The disease was treated with buntanetap and antihypertensive drugs.

By combining buntanetap with antihypertensive drugs such as alpha-adrenergic blockers, the problem of existing antihypertensive drugs not being approved for neurodegenerative diseases was solved, resulting in significantly enhanced therapeutic effects, slowed disease progression, and improved symptoms.

CN123124972APending Publication Date: 2026-11-17ANNOVIS BIO INC
View PDF 42 Cites 0 Cited by

Patent Information

Application Number
CN202480090977.9
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Priority Date
2024-04-15
Filing Date
2024-09-27
Publication Date
2026-11-17

AI Technical Summary

Technical Problem

Existing antihypertensive drugs are not approved for the treatment of neurodegenerative diseases, and the use of buntanetap or similar compounds alone has limited efficacy and cannot effectively slow down or delay neuronal cell death.

Method used

By combining buntanetap or similar compounds with antihypertensive drugs, especially alpha-adrenergic blockers such as terazosin, doxazosin, and alfuzosin, the combined effect can be synergistically used to treat neurodegenerative diseases, cardiovascular diseases, and benign prostatic hyperplasia, at a lower dose than when used alone, but with significantly enhanced efficacy.

Benefits of technology

It achieved at least four times the therapeutic effect of using buntanetap or antihypertensive drugs alone, reduced the incidence of adverse effects, enhanced efficacy, improved cognitive and motor function, and reduced disease symptoms.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure FT_1
    Figure FT_1
  • Figure FT_2
    Figure FT_2
  • Figure FT_3
    Figure FT_3
Patent Text Reader

Abstract

This invention relates to methods and pharmaceutical compositions for the effective treatment, inhibition, prevention, mitigation, or delay of the onset of neurodegenerative diseases in mammals (e.g., humans) by administering in combination effective amounts of compounds selected from the group consisting of formulas (I), (II), (III), or (IV), or pharmaceutically acceptable salts thereof, and antihypertensive agents (α-adrenergic blockers). In some embodiments, the mammal is a healthy human or a human with cognitive impairment, with or without hypertension.
Need to check novelty before this filing date? Find Prior Art

Description

[0001] This application claims the benefit of U.S. Provisional Application No. 63 / 633,912, filed April 15, 2024, which is incorporated herein by reference. Technical Field

[0002] This patent application relates to a method for treating neurodegenerative diseases, cardiovascular diseases, and benign prostatic hyperplasia by administering buntanetap or related compounds along with an antihypertensive drug (e.g., an alpha-adrenergic blocker). Background Technology

[0003] High-speed rail increases the translation of neurotoxic aggregates, leading to impaired axonal transport, inflammation, neuronal death, and cognitive and motor function impairments.

[0004] For unknown reasons, iron levels are high in the "ill" brain, which induces iron regulatory protein 1 to release mRNA encoding neurotoxic aggregates, leading to upregulation of translation and synthesis, resulting in excessive production of neurotoxic aggregates in the diseased brain.

[0005] Abeta is a well-known contributing factor to the development of Alzheimer's disease. Abeta plaques are found throughout the brains of people who develop cognitive symptoms of Alzheimer's disease.

[0006] Lewy body dementia is the second most common form of neurodegenerative dementia after Alzheimer's disease. Lewy body dementia affects memory, motor function, and cognition.

[0007] Buntanetap is a translation inhibitor of various neurotoxic aggregates.

[0008] Recent studies have revealed that cardiovascular diseases, including hypertension, are risk factors for cognitive decline and dementia through brain perfusion injury, changes in brain structure, inflammation, β-amyloid deposition, and neuroendocrine disorders. See, e.g., Morley JE. Cognition and chronic disease. J Am Med Dir Assoc 2017; 18: 369–371; Greaves D, Psaltis PJ, Ross TJ, et al. Cognitive outcomes following coronary artery bypass grafting: a systematic review and meta-analysis of 91,829 patients. Int J Cardiol 2019; 289: 43–49; Cardiogenic dementia. Lancet1977; 309: 27–28; Leng etal. Cognitive impairment, and 30-day rehospitalization rate in patients with acute heart failure: a systematic review and meta-analysis. Indian Heart J2019; 71: 52–59; Irimata KE, Dugger BN, Wilson JR. Impact of the presence ofselect cardiovascular risk factors on cognitive changes among dementia subtypes.Curr Alzheimer Res 2018; 15: 1032–1044; Yuan JQ, Lv YB, Chen HS, etal. Association between late-life blood pressure and the incidence ofcognitive impairment: a community-based prospective cohort study. J Am MedDir Assoc 2019; 20: 177–182.e172; Irimata KE, Dugger BN, Wilson JR. Impact ofthe presence of select cardiovascular risk factors on cognitive changes amongdementia subtypes. Curr Alzheimer Res 2018; 15: 1032–1044; Jefferson AL.Cardiac output as a potential risk factor for abnormal brain aging. JAlzheimer’s Dis 2010; 20: 813–821; Stefanidis KB, Askew CD, Greaves K, et al.The effect of non-stroke cardiovascular disease states on risk for cognitivedecline and dementia: a systematic and meta-analytic review. Neuropsychol Rev2018; 28: 1–15; Haring B, Leng X, Robinson J, Johnson KC, Jackson RD, BeythR, Wactawski-Wende J, von Ballmoos MW, Goveas JS, Kuller LH, Wassertheil-Smoller S.Cardiovascular disease and cognitive decline in postmenopausal women: results from the Woman's Health Initiative Memory Study, J Am HeartAssoc. 2013 Dec 18;2(6):e000369. .

[0009] Antihypertensive drugs are not currently approved by the US FDA for the treatment of neurodegenerative diseases. Summary of the Invention

[0010] The purpose of this invention is to provide a treatment for neurodegenerative diseases.

[0011] Another object of the present invention is to provide a treatment for cardiovascular diseases.

[0012] Another object of the present invention is to provide a treatment for benign prostatic hyperplasia.

[0013] Another objective of this invention is to prevent, slow down, or delay the development of neurodegenerative diseases that lead to the death of neuronal cells.

[0014] In accordance with the foregoing and other objectives, this invention relates in part to a method of treating neurodegenerative diseases by administering buntanetap, a buntanetap-like compound described herein, pharmaceutically acceptable salts and complexes thereof, and an antihypertensive agent (e.g., an alpha-adrenergic blocker), wherein the amount of at least one of these agents administered is at least twice the amount of that agent required to provide any meaningful therapeutic effect if the agent were administered alone (i.e., as a monotherapy, without administering another agent). However, the therapeutic effect provided by administering (i) buntanetap or a buntanetap-like compound and (ii) the said antihypertensive agent is (a) greater than the therapeutic effect provided by administering the same amount of buntanetap or a buntanetap-like compound alone (if any), and (b) greater than the therapeutic effect provided by administering the same amount of the antihypertensive agent alone (if any). In the method of this invention, buntanetap or a buntanetap-like compound and the said antihypertensive agent may be administered in the same or different dosage forms. In addition to buntanetap and the aforementioned antihypertensive drugs, the dosage form may contain one or more pharmaceutically acceptable excipients.

[0015] The present invention also relates in part to a method of treating a disease by administering (i) buntanetap or a compound similar to buntanetap and (ii) an antihypertensive drug to a person in need, wherein the buntanetap and the antihypertensive drug are administered in synergistic amounts.

[0016] The present invention further relates to a method for treating a disease by administering to a human patient in need a certain amount of buntanetap or a similar compound and a certain amount of an antihypertensive drug, wherein the amount of the antihypertensive drug is subtherapeutic when administered without buntanetap or a similar compound, but therapeutic when administered with the same amount of buntanetap or a similar compound.

[0017] The present invention also relates to a method of treating a disease by administering to a human patient in need a certain amount of buntanetap or a similar compound and a certain amount of an antihypertensive drug, wherein the amount of buntanetap or a similar compound is subtherapeutic when administered without the antihypertensive drug, but therapeutic when administered with the antihypertensive drug.

[0018] Diseases that can be treated according to the present invention include, for example, neurodegenerative diseases, cardiovascular diseases, and benign prostatic hyperplasia.

[0019] The present invention further relates to a method for treating neurodegenerative diseases, the method comprising administering to a human patient in need a certain amount of buntanetap or a similar compound and a certain amount of an antihypertensive drug, wherein the amount of the antihypertensive drug is subtherapeutic when administered without buntanetap or a similar compound, but therapeutic when administered with the same amount of buntanetap or a similar compound, wherein the antihypertensive drug is an α1-antagonist.

[0020] The present invention also relates to a method for treating a disease, the method comprising administering to a human patient in need a certain amount of buntanetap or a similar compound and a certain amount of an antihypertensive drug, wherein the amount of the buntanetap or similar compound is subtherapeutic when administered without the antihypertensive drug, but therapeutic when administered with the antihypertensive drug, wherein the antihypertensive drug is an α1 antagonist.

[0021] Administration of (i) buntanetap or a compound similar to buntanetap and (ii) an antihypertensive drug can provide at least four times the therapeutic effect compared to administration of the antihypertensive drug alone. In some embodiments, the improvement provided by administration of buntanetap or a compound similar to buntanetap and the antihypertensive drug is 5 to 10 times greater than the improvement provided by administration of the antihypertensive drug alone.

[0022] The present invention covers a method of treating a disease by administering (i) buntanetap or a compound similar to buntanetap described herein and (ii) an antihypertensive drug to a person in need, wherein the amount of at least one of these drugs administered is at least 5, 8 or 10 times less than the amount of the drug required if administered alone to provide any meaningful therapeutic effect.

[0023] The present invention covers a method of treating a disease by administering (i) buntanetap or a compound similar to buntanetap described herein and (ii) an α1 antagonist to a person in need, wherein at least one of these agents is administered in an amount at least 5, 8, or 10 times less than the amount of the agent required if administered alone to provide any meaningful therapeutic effect.

[0024] Therefore, the method of the present invention may allow (i) to administer (a) a lower dose of buntanetap or a compound similar to buntanetap, and / or (b) a lower dose of an antihypertensive drug (e.g., an α1 antagonist), (ii) to reduce the incidence and / or severity of adverse effects, and / or (iii) to increase the efficacy of (a) buntanetap or a compound similar to buntanetap and / or (b) the antihypertensive drug.

[0025] For example, in some embodiments, the present invention relates to a method of treating a disease by administering (i) buntanetap or a similar compound described herein and (ii) an antihypertensive drug to a person in need, wherein the buntanetap or similar compound is administered in an amount of less than 1 mg, less than 0.9 mg, or less than 0.8 mg per day. In some of these embodiments, the amount of buntanetap or similar compound administered may be, for example, from about 0.01 mg to about 0.7 mg, and may be administered orally, parenterally, or transdermally.

[0026] The present invention also relates in part to a method of treating a disease by administering (i) buntanetap or a compound similar to buntanetap described herein and (ii) an antihypertensive drug to a person in need, wherein the antihypertensive drug is administered in an amount of less than 1 mg, less than 0.5 mg, or less than 0.1 mg per day. In some of these embodiments, the amount of the antihypertensive drug administered may be, for example, from about 0.01 mg to about 0.5 mg, and may be administered orally, parenterally, or transdermally.

[0027] The present invention also relates in part to a method of treating a disease by administering (i) buntanetap or a compound similar to buntanetap described herein and (ii) an antihypertensive drug to a person in need, wherein the amount of the antihypertensive drug is less than that of buntanetap or a compound similar to buntanetap.

[0028] This invention also relates in part to a method for treating neurodegenerative diseases, the method comprising administering to a person in need a formulation comprising buntanetap or a pharmaceutically acceptable salt thereof and an alpha-adrenergic blocker, wherein the alpha-adrenergic blocker is selected from the group consisting of terazosin, doxazosin, alfuzosin, and pharmaceutically acceptable salts thereof, and the neurodegenerative disease is selected from the group consisting of Alzheimer's disease, chronic traumatic encephalopathy, frontotemporal dementia, Parkinson's disease, alpha-synucleinopathy, prion disease, Down syndrome, Huntington's disease, amyotrophic lateral sclerosis, and multiple sclerosis. In these embodiments, the formulation may be administered orally, parenterally, intravenously, subcutaneously, sublingually, via suppository, intranasally, topically, transdermally, or via a subcutaneous implant. The formulation may, for example, comprise about 0.1 mg to about 0.9 mg and may be administered orally once daily.

[0029] The present invention also relates to a method for treating neurodegenerative diseases, the method comprising administering, to a person in need, in combination: (1) a quantity of buntanetap or a pharmaceutically acceptable salt thereof, and (2) a quantity of an alpha-adrenergic blocker. The alpha-adrenergic blocker may, for example, be selected from the group consisting of terazosin, doxazosin, alfuzosin, and pharmaceutically acceptable salts thereof. In some embodiments, compounds (1) and (2) are administered separately, but such that they provide overlapping therapeutic effects. In some embodiments, the amount of buntanetap or a pharmaceutically acceptable salt thereof is from about 0.1 mg to about 0.9 mg, and buntanetap or a pharmaceutically acceptable salt thereof is administered orally once daily.

[0030] This invention also relates in part to a pharmaceutical composition comprising buntanetap or a pharmaceutically acceptable salt thereof, an alpha-adrenergic blocker; and at least one pharmaceutically acceptable excipient, wherein the alpha-adrenergic blocker is selected from the group consisting of terazosin, doxazosin, alfuzosin, and pharmaceutically acceptable salts thereof. The pharmaceutical composition may be, for example, a tablet. The tablet may contain about 0.1 mg to about 0.9 mg of buntanetap or a pharmaceutically acceptable salt thereof. In some of these embodiments, the alpha-adrenergic blocker is terazosin or a pharmaceutically acceptable salt thereof.

[0031] In some embodiments, the antihypertensive drug is not a phosphodiesterase inhibitor.

[0032] Diseases that can be treated by the methods of the present invention include, for example, neurodegenerative diseases (such as Alzheimer's disease, Lewy body dementia, frontotemporal dementia, other forms of dementia, chronic traumatic encephalopathy, tau protein disease, alpha-synucleinosis, prions, Down syndrome, Huntington's disease, multiple sclerosis, amyotrophic lateral sclerosis), dementia, Parkinson's disease, cardiovascular diseases, and benign prostatic hyperplasia.

[0033] Depending on the disease being treated, the therapeutic effects provided by the method according to the invention may include, for example, a reduction in the symptoms and / or severity of neurodegenerative diseases, improvement in cognitive function, improvement in motor function, a reduction in blood pressure, and a reduction in the symptoms of benign prostatic hyperplasia.

[0034] This invention relates in part to a method for treating a neurodegenerative disease by administering (i) buntanetap or a compound similar to buntanetap and (ii) an antihypertensive drug to a human patient in need, wherein the neurodegenerative disease is Alzheimer's disease and the treatment effect is an improvement in mental state.

[0035] The present invention also relates in part to a method for treating neurodegenerative diseases by administering (i) buntanetap or a compound similar to buntanetap and (ii) an antihypertensive drug to a human patient in need, wherein the neurodegenerative disease is dementia (e.g., Parkinson's dementia, Lewy body dementia, frontotemporal dementia, mild cognitive impairment, etc.) and the treatment effect is an improvement in cognitive and mental state.

[0036] Improvements in mental state can be measured, for example, by changes in scores on cognitive scales such as ADAS-Cog11.

[0037] The present invention also relates in part to a method for treating a neurodegenerative disease, the method comprising administering (i) buntanetap or a compound similar to buntanetap and (ii) an antihypertensive drug to a human patient in need, wherein the neurodegenerative disease is Parkinson's disease, and the therapeutic effect is an improvement in motor function. The improvement in motor function can be measured, for example, by changes in the MDS-UPDRS or a portion thereof.

[0038] The present invention also relates in part to a method of treating Parkinson's disease by administering (i) buntanetap or a compound similar to buntanetap and (ii) an antihypertensive drug to a human patient in need, wherein the therapeutic effect is, for example, improvement in postural instability, gait difficulty, tremor or cognition.

[0039] This invention also relates in part to a method for treating benign prostatic hyperplasia (BPH), the method comprising administering (i) buntanetap or a compound similar to buntanetap and (ii) an antihypertensive drug (e.g., an α1-antagonist) to a human patient in need. Improvement in BPH can be measured, for example, by changes in the International Prostate Symptom Score.

[0040] The present invention further relates in part to a method for inhibiting, preventing or treating neurodegenerative diseases such as Alzheimer's disease by administering buntanetap, a compound similar to buntanetap described herein, a pharmaceutically acceptable salt and complex thereof, an α-adrenergic blocker and one or more pharmaceutically acceptable excipients, wherein the α-adrenergic blocker is an α1 antagonist.

[0041] The present invention further relates in part to a method for inhibiting, preventing or treating neurodegenerative diseases such as Alzheimer's disease by administering buntanetap, a compound similar to buntanetap described herein, a pharmaceutically acceptable salt and complex thereof, and an antihypertensive drug to a patient with hypertension.

[0042] The present invention further relates in part to a method of treating a disease by administering buntanetap or a similar compound and an antihypertensive drug to a human patient in need at a weight ratio that provides a synergistic therapeutic effect, compared to administering buntanetap without the antihypertensive drug and / or administering the antihypertensive drug without buntanetap.

[0043] The present invention also relates in part to a method of treating a disease by administering to a human patient in need a certain amount of buntanetap or a similar compound and a certain amount of an antihypertensive drug, wherein the amount of the antihypertensive drug is subtherapeutic when administered without buntanetap or a similar compound, but therapeutic when administered with the same amount of buntanetap or a similar compound.

[0044] The present invention also relates in part to a method of treating a disease by administering to a human patient in need a certain amount of buntanetap or a similar compound and a certain amount of an antihypertensive drug, wherein the amount of buntanetap or a similar compound is subtherapeutic when administered without the antihypertensive drug, but therapeutic when administered with the same amount of the antihypertensive drug.

[0045] The present invention also relates in part to a method for treating dementia, the method comprising administering, in an amount providing a synergistic therapeutic effect, to a human patient in need of a compound such as buntanetap or a similar compound as well as an antihypertensive drug, in a manner that provides a synergistic therapeutic effect, compared to administering buntanetap without the antihypertensive drug and / or administering the antihypertensive drug without the buntanetap.

[0046] The present invention also relates in part to a method for treating Alzheimer's disease, the method comprising administering, in an amount providing a synergistic therapeutic effect, to a human patient in need of a compound such as buntanetap or a similar compound as well as an antihypertensive drug, in a manner that provides a synergistic therapeutic effect, compared to administering buntanetap without the antihypertensive drug and / or administering the antihypertensive drug without the buntanetap.

[0047] The present invention also relates in part to a method for treating Lewy body dementia, the method comprising administering, in an amount providing a synergistic therapeutic effect, to a human patient in need of buntanetap or a similar compound as well as an antihypertensive drug, compared to administering buntanetap without the antihypertensive drug and / or administering the antihypertensive drug without buntanetap.

[0048] The present invention also relates in part to a method of treating Parkinson's disease, the method comprising administering, to a human patient in need, a buntanetap or a similar compound and an antihypertensive drug in an amount that provides a synergistic therapeutic effect, compared to administering buntanetap without the antihypertensive drug and / or administering the antihypertensive drug without buntanetap.

[0049] The invention further relates in part to a method for inhibiting, preventing or treating neurodegenerative diseases such as alpha-synucleinosis by administering buntanetap or a compound similar to buntanetap, along with an antihypertensive drug and one or more pharmaceutically acceptable excipients.

[0050] The invention further relates in part to a method for inhibiting, preventing or treating neurodegenerative diseases such as prion diseases by administering buntanetap or a compound similar to buntanetap, along with an antihypertensive drug and one or more pharmaceutically acceptable excipients.

[0051] The invention further relates in part to a method for inhibiting, preventing or treating neurodegenerative diseases such as Down syndrome by administering buntanetap or a compound similar to buntanetap, along with an antihypertensive drug and one or more pharmaceutically acceptable excipients.

[0052] The invention further relates in part to a method for inhibiting, preventing or treating neurodegenerative diseases such as Huntington's disease by administering buntanetap or a compound similar to buntanetap, along with an antihypertensive drug and one or more pharmaceutically acceptable excipients.

[0053] The present invention further relates in part to a method for inhibiting, preventing or treating neurodegenerative diseases such as amyotrophic lateral sclerosis by administering buntanetap or a compound similar to buntanetap, along with an antihypertensive drug and one or more pharmaceutically acceptable excipients.

[0054] Another object of the present invention is to inhibit, prevent, slow down, or reduce the overexpression of neurotoxic aggregates in patients with hypertension who do not exhibit symptoms of neurological disorders or neurodegenerative diseases, or who exhibit symptoms of neurological disorders or neurodegenerative diseases. The method comprises or consists of administering to the person a therapeutically effective amount of buntanetap, an active metabolite of buntanetap, a therapeutically effective analog of buntanetap, a compound similar to buntanetap described herein, a pharmaceutically acceptable salt and complex thereof, and a blood pressure medication administered at a therapeutic dose for treating hypertension or at a subtherapeutic dose compared to the dose of a blood pressure medication for treating hypertension. Examples of neurotoxic aggregates treatable by the method of the present invention include APP (amyloid precursor protein), Aβ (amyloid β-peptide, a fragment of APP), SOD (superoxide dismutase) protein, Tau, α-synuclein (SNCA), infectious spongiform encephalopathy (TSE) prions, TDP43, and huntingtin protein (HTT).

[0055] The present invention also relates in part to a method for treating, inhibiting, or alleviating neurological disorders or diseases in mammals (e.g., humans) such as Alzheimer's disease, Lewy body dementia, frontotemporal dementia, other dementias, chronic traumatic encephalopathy, tau proteinosis, Parkinson's disease, alpha-synucleinosis, prions, Down syndrome, Huntington's disease, amyotrophic lateral sclerosis, multiple sclerosis, other neurodegenerative diseases characterized by protein misfolding, aggregation, and accumulation in the brain leading to inflammation and ultimately cell death, and the onset of hypertension, said method comprising or consisting of: administering to said human a therapeutically effective amount of buntanetap, an active metabolite of buntanetap, a therapeutically effective analogue of buntanetap, a compound similar to buntanetap described herein, a pharmaceutically acceptable salt and complex thereof, and a blood pressure medication and one or more pharmaceutically acceptable excipients.

[0056] This invention further relates in part to a method for preventing, treating, inhibiting, or slowing down neurodegenerative diseases, comprising administering an antihypertensive drug and a compound selected from the group consisting of formulas (I), (II), (III), and (IV) to a person in need: , (III), and (IV).

[0057] The present invention further relates in part to a method of treating a healthy person at risk of developing such neurodegenerative diseases, comprising administering to the healthy person an alpha-adrenergic blocker and a compound selected from the group consisting of formulas (I), (II), (III), and (IV): , (III), and (IV).

[0058] In formulas (I) and (II), R1 and R2 are independently hydrogen, branched or straight-chain C. 1- R3 is a C8 alkyl, substituted or unsubstituted aryl, heteroaryl or aralkyl; R3 is a branched or straight-chain C1-C4 alkyl or heteroaryl or C4-C8 alkyl or heteroaryl, or a substituted or unsubstituted aryl; X and Y are independently O, S, alkyl, hydrocarbon moiety, C(H)R4 or NR5, wherein R4 and R5 are independently hydrogen, oxygen, branched or straight-chain C1-C8 alkyl, C2-C8 alken or C2-C8 ynyl, aralkyl, or a substituted or unsubstituted aryl; and R6 is hydrogen, C1-C8 alkyl, C1-C8 alken, C2-C8 ynyl, aralkyl or a substituted or unsubstituted aryl, or (CH2). n R7, wherein R7 is a hydroxyl, alkoxy, cyano, ester, carboxylic acid, substituted or unsubstituted amino group, and n is 1 to 4. In some embodiments, the method includes using a second therapeutic agent to treat, prevent, delay, or slow the onset of neurodegenerative diseases such as Alzheimer's disease.

[0059] In some embodiments, compounds selected from the group consisting of formulas (I), (II), (III), and (IV) do not contain any significant acetylcholinesterase (ACHE) inhibitory activity and do not contain any butyrylcholinesterase (BCHE) activity.

[0060] In formula (III), R1 and R2 are independently hydrogen, branched or straight-chain C1–C8 alkyl, substituted or unsubstituted aryl, heteroaryl, or aralkyl; R3 is branched or straight-chain C1–C4 alkyl or heteroaryl or C4–C8 alkyl or heteroaryl, or substituted or unsubstituted aryl; X is NR5, wherein R5 is C 2-8 alkenyl, C 2-8 Alkyne or aralkyl, and Y is selected from C(H)R4 or NR5, wherein R4 and R5 are independently hydrogen, branched or straight-chain C 1-8 Alkyl or heteroalkyl, alkenyl or C2–C8 ynyl, aralkyl.

[0061] In some embodiments, the compounds of formula (I) and (II) are (+)-enantiomers. In other embodiments, the compounds of formula (I) and (II) are (-)-enantiomers.

[0062] In some embodiments, the compound of formula (I) is buntanetap and has the following structure: .

[0063] In some embodiments, a compound selected from the group consisting of formulas (I), (II), and (III) is buntanetap or a pharmaceutically acceptable salt thereof, administered orally once daily at a dose of about 0.01 mg to about 0.9 mg for at least three months, together with a therapeutically effective amount of an antihypertensive drug, to a person in need for at least three months, and said administration results in an increase in the person's cognitive test score.

[0064] In the method of the present invention, buntanetap or a compound similar to buntanetap and the antihypertensive drug can be administered as a free base, a pharmaceutically acceptable salt, a metabolite, a prodrug, a complex, or a mixture thereof, via the same or different routes of administration and at the same or different times.

[0065] The present invention also relates in part to a method for inhibiting, preventing, or treating neurodegenerative diseases by administering buntanetap, a buntanetap-like compound described herein, pharmaceutically acceptable salts and complexes thereof, and an antihypertensive drug to a human patient in need, wherein the buntanetap or a buntanetap-like compound enhances the therapeutic effect of the antihypertensive drug, and / or the antihypertensive drug enhances the therapeutic effect of the buntanetap or a buntanetap-like compound by at least 50% (e.g., 100 to 900%).

[0066] The present invention also relates in part to a method of treating Alzheimer's disease by administering buntanetap, a buntanetap-like compound described herein, a pharmaceutically acceptable salt and complex thereof, and an antihypertensive drug to a human patient in need, wherein the buntanetap or a buntanetap-like compound enhances the therapeutic effect of the antihypertensive drug, and / or the antihypertensive drug enhances the therapeutic effect of the buntanetap or a buntanetap-like compound by at least 50% (e.g., 100 to 900%).

[0067] The present invention also relates in part to a method for inhibiting, preventing, or treating neurodegenerative diseases by administering buntanetap, a buntanetap-like compound described herein, pharmaceutically acceptable salts and complexes thereof, and an α1-antagonist to a human patient in need, wherein the buntanetap or a buntanetap-like compound enhances the therapeutic effect of the α1-antagonist, and / or the α1-antagonist enhances the therapeutic effect of the buntanetap or a buntanetap-like compound by at least 50% (e.g., 100 to 900%).

[0068] The present invention also relates in part to a method of treating benign prostatic hyperplasia by administering buntanetap, a buntanetap-like compound described herein, a pharmaceutically acceptable salt and complex thereof, and an antihypertensive drug to a human patient in need, wherein the buntanetap or a buntanetap-like compound enhances the therapeutic effect of the antihypertensive drug, and / or the antihypertensive drug enhances the therapeutic effect of the buntanetap or a buntanetap-like compound by at least 50% (e.g., 100 to 900%).

[0069] The present invention further relates in part to a method of treating a disease by administering buntanetap or a similar compound and an antihypertensive drug to a human patient in need at a weight ratio that provides a synergistic therapeutic effect, compared to administering buntanetap without the antihypertensive drug and / or administering the antihypertensive drug without buntanetap. In some embodiments, the synergistic ratio by weight is 10 to 10,000, 10 to 5,000, 10 to 1,000, 10 to 500, or 10 to 250.

[0070] The present invention also relates in part to a method for treating cardiovascular disease, the method comprising administering, to a human patient in need, a buntanetap or a similar compound and an antihypertensive drug in an amount that provides a synergistic therapeutic effect, compared to administering buntanetap without the antihypertensive drug and / or administering the antihypertensive drug without buntanetap.

[0071] In some implementations, buntanetap is administered in amounts of about 0.01 to about 120 mg and numbers in between, preferably once daily. Therefore, in some embodiments, the dosage of buntanetap may be, for example, 0.01 mg, 0.02 mg, 0.05 mg, 0.1 mg, 0.2 mg, 0.3 mg, 0.4 mg, 0.5 mg, 0.6 mg, 0.7 mg, 0.8 mg, 0.9 mg, 1 mg, 2 mg, 3 mg, 4 mg, 5 mg, 6 mg, 7 mg, 8 mg, 9 mg, 10 mg, 11 mg, 12 mg, 13 mg, 14 mg, 15 mg, 16 mg, 17 mg, 18 mg, 19 mg, 20 mg, 21 mg, 22 mg, 23 mg, 24 mg, 25 mg, 26 mg, 27 mg, 28 mg, 29 mg, 30 mg, 31 mg, 32 mg, 33 mg, 34 mg, 35 mg, 36 mg, 37 mg, 38 mg, 39 mg, 40 mg, 41 mg, 42 mg, 43 mg, 44 mg. mg, 45 mg, 46 mg, 47 mg, 48 mg, 49 mg, or 50 mg, and numbers between these. In some preferred embodiments, buntanetap is administered orally at doses of about 0.1 mg to about 5 mg, about 0.1 mg to about 2 mg, or about 0.1 mg to about 0.9 mg. In other preferred embodiments, buntanetap is administered intravenously at doses of about 0.01 mg to about 0.25 mg / day. In other preferred embodiments, buntanetap is administered intraperitoneally / intramuscularly (IP / IM) at doses of about 0.3 mg / day to about 0.7 mg / day. In some preferred embodiments, buntanetap is administered co-administered with any antihypertensive drugs further described in subsequent paragraphs below.

[0072] In some embodiments, buntanetap is administered orally once or twice daily in an amount of about 0.01 mg to about 0.9 mg, and the antihypertensive drug is administered once or twice daily in an amount of about 0.1 mg to about 750 mg.

[0073] In some embodiments, buntanetap is administered orally once or twice daily in an amount of about 0.01 mg to about 0.9 mg, and the antihypertensive drug is an α1 antagonist administered once or twice daily in an amount of about 0.1 mg to about 50 mg.

[0074] In some embodiments, a compound selected from the group consisting of formulas (I), (II), and (III) is buntanetap or a pharmaceutically acceptable salt thereof, administered orally once daily at a dose of about 0.01 mg to about 0.9 mg for at least three months, in combination with a therapeutically effective amount of an α1-antagonist, wherein the α1-antagonist is selected from the group consisting of terazosin, doxazosin, alfuzosin, and any pharmaceutically acceptable salt thereof.

[0075] In some embodiments, buntanetap is administered orally at doses of, for example, about 2 mg to about 80 mg, about 3 mg to about 60 mg, or about 5 mg to about 30 mg. In other embodiments, buntanetap is administered intravenously at a dose of about 0.1 to about 25 mg / day. In other embodiments, buntanetap is administered intraperitoneally / intramuscularly (IP / IM) at a dose of about 0.3 mg / day to about 70 mg / day.

[0076] In some embodiments of each of the above methods, the oral pharmaceutical composition contains about 0.1 mg to about 5 mg buntanetap or a pharmaceutically acceptable salt thereof, the IP / IM pharmaceutical composition contains about 0.03 to about 0.7 mg buntanetap or a pharmaceutically acceptable salt thereof, and the intravenous (IV) pharmaceutical preparation contains about 0.01 to about 0.25 mg buntanetap or a pharmaceutically acceptable salt thereof.

[0077] In some embodiments of each of the above methods, in order to minimize the incidence of side effects, buntanetap or a pharmaceutically acceptable salt thereof is administered multiple times a day, or in a controlled-release or sustained-release formulation that releases buntanetap or a pharmaceutically acceptable salt thereof over 4 to 24 hours, preferably 8 to 24 hours or 12 to 24 hours.

[0078] In some preferred embodiments of the method described herein, the peak plasma circulation level of buntanetap in humans ranges from, for example, from about 0.01 ng / mL to about 200 ng / mL, in some embodiments from about 0.2 ng / mL to about 20 ng / mL, more preferably from about 0.37 ng / mL to about 12 ng / mL, and any number or integer between therebetween. In some preferred embodiments, the peak plasma circulation level is reached approximately 1 to 3 hours after administration of buntanetap to the human body. In some embodiments, the steady-state plasma concentration of buntanetap in the brain is about 0.01, 0.02, 0.03, 0.04, 0.05, 0.06, 0.07, 0.08, 0.09, 0.1, 0.2, 0.3, 0.4, 0.5, 0.6, 0.7, 0.8, 0.9, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20 ng / mL. In some embodiments, the half-life of buntanetap in cerebrospinal fluid after administration is about 12 hours, and the half-life of buntanetap in plasma after administration is about 5 hours. In some embodiments, administration of buntanetap to humans results in brain levels of buntanetap that are about 4 to about 10 times the plasma levels of buntanetap in these patients. In some embodiments, the concentration of buntanetap in the human brain is from about 0.8 ng / g to about 304 ng / g, and in other embodiments it is from about 0.3 ng / g to about 100 ng / g.

[0079] For each of the above methods, buntanetap, its pharmaceutically acceptable salts, analogs or similar compounds described herein may be administered, for example, orally, parenterally, sublingually, via suppositories, intranasally, topically, transdermally, or via subdermal implants.

[0080] In some embodiments, the antihypertensive drug is administered in amounts of about 0.01 to about 750 mg and any number between these figures.

[0081] For each of the above methods, buntanetap, its pharmaceutically acceptable salts, analogs or similar compounds described herein may be administered, for example, orally, parenterally, sublingually, via suppositories, intranasally, topically, transdermally, or via subdermal implants.

[0082] The present invention also relates in part to a method for treating, preventing, delaying or slowing down neurodegenerative diseases such as dementia, comprising administering to the person a compound selected from the group consisting of formula (I), formula (II), formula (III) or formula (IV) and an α-adrenergic blocker.

[0083] The present invention further relates in part to a method for treating, preventing, delaying or slowing down neurodegenerative diseases such as Alzheimer's disease, comprising administering to the person a compound selected from the group consisting of formula (I), formula (II), formula (III) or formula (IV) and an α-adrenergic blocker.

[0084] The present invention further relates in part to a method for treating, preventing, delaying or slowing down neurodegenerative diseases such as Lewy body dementia, comprising administering to the person a compound selected from the group consisting of formula (I), formula (II), formula (III) or formula (IV) and an α-adrenergic blocker.

[0085] The present invention further relates in part to a method for treating, preventing, delaying or slowing down neurodegenerative diseases such as α-synucleinosis, comprising administering to the person a compound selected from the group consisting of formula (I), formula (II), formula (III) or formula (IV) and an α-adrenergic blocker.

[0086] The present invention further relates in part to a method for treating, preventing, delaying or slowing down neurodegenerative diseases such as α-synucleinosis, comprising administering to the person a compound selected from the group consisting of formula (I), formula (II), formula (III) or formula (IV) and an α-adrenergic blocker.

[0087] The α-adrenergic blocker used in the method of the present invention may, for example, be selected from the group consisting of terazosin, doxazosin, alfuzosin, and any pharmaceutically acceptable salts thereof.

[0088] In some embodiments, the compound is administered according to the formulations and methods of the present invention to patients who have already exhibited symptoms of a neurological disorder. In other embodiments, the compound is administered according to the formulations and methods of the present invention to patients who have already exhibited cardiovascular disease (e.g., hypertension). In some embodiments, the compound is administered according to the formulations and methods of the present invention to patients who have already exhibited symptoms of both a neurological disorder and cardiovascular disease (e.g., hypertension). In still other embodiments, the compound is administered according to the formulations and methods of the present invention to patients (human subjects) who have not exhibited any neurological or cardiovascular problems but may be at risk of future neurological and / or cardiovascular problems.

[0089] The antihypertensive drugs or agents used in the methods of the present invention may include, for example, thiazide diuretics, ACE (angiotensin-converting enzyme) inhibitors and calcium channel blockers (CCBs), angiotensin II receptor blockers (ARBs), calcium channel blockers (including dihydropyridine and non-dihydropyridine), direct vasodilators, diuretics (including potassium-sparing diuretics, loop diuretics, thiazide and thiazide-type diuretics), α-blockers and β-blockers.

[0090] For the purposes of this invention, antihypertensive drugs are also considered to encompass alpha-adrenergic blockers, particularly terazosin, doxazosin, alfuzosin, and their pharmaceutically acceptable salts. In some embodiments, in addition to blocking alpha-adrenergic receptors, these compounds also bind to and activate adenosine triphosphate (ATP)-generating enzymes in glycolysis. Activation of ATP-generating enzymes in glycolysis can increase energy availability in the brain and may prevent or slow the accumulation of neurodegenerative proteins in the brain.

[0091] The compounds of the present invention can be administered separately or together via routes selected from the group consisting of: oral, parenteral, sublingual, suppository, intranasal, topical, transdermal, intravenous, subcutaneous, intraperitoneal, and percutaneous implants. In some embodiments, the compounds are administered long-term to treat, prevent, delay, or slow neurodegenerative diseases such as Alzheimer's disease in mammals, such as humans.

[0092] In some preferred embodiments, the compound to be administered in combination is buntanetap and an alpha-adrenergic blocker, and the buntanetap is administered together with the alpha-adrenergic blocker in the amount set forth in this disclosure.

[0093] In some embodiments, the compound (e.g., buntanetap and an antihypertensive drug) is administered in combination to a mammal (e.g., a human) exhibiting symptoms of hypertension. In some embodiments, the mammal (e.g., a human subject or human patient) exhibits symptoms of a neurological disorder or neurodegenerative disease. In some embodiments, the mammal (e.g., a human subject or human patient) does not exhibit symptoms of a neurological disorder or neurodegenerative disease.

[0094] In some embodiments, the buntanetap or a pharmaceutically acceptable salt thereof is (i) administered orally once daily in an amount of about 0.01 mg to about 120 mg; (ii) administered intravenously in an amount of about 0.01 mg to about 25 mg / day; or (ii) administered intraperitoneally / intramuscularly (IP / IM) in a dose of about 0.03 mg to about 70 mg / day.

[0095] In some embodiments, the compounds of formulas (I), (II), and (III) are administered separately from the antihypertensive drug (e.g., an alpha-adrenergic blocker), but in a way that they provide overlapping therapeutic effects.

[0096] In some embodiments, the present invention further relates to a pharmaceutical composition comprising a therapeutically effective amount of a compound selected from the group consisting of formulas (I), (II), and (III): (III)

[0097] in,

[0098] In equations (I) and (II),

[0099] R1 and R2 are independently hydrogen, branched or straight-chain C. 1- C8 alkyl, substituted or unsubstituted aryl, heteroaryl or aralkyl;

[0100] R3 is a branched or straight-chain C1-C4 alkyl or heteroalkyl or C4-C8 alkyl or heteroalkyl, or a substituted or unsubstituted aryl group;

[0101] X and Y are independently O, S, alkyl, hydrocarbon moiety, C(H)R4 or NR5, wherein R4 and R5 are independently hydrogen, oxygen, branched or straight-chain C1-C8 alkyl, C2-C8 alkenyl or C2-C8 alkynyl, aralkyl, or substituted or unsubstituted aryl; and

[0102] R6 is hydrogen; C1-C8 alkyl, C1-C8 alkenyl, C2-C8 alkynyl, aralkyl, or substituted or unsubstituted aryl, or (CH2). n R7, wherein R7 is a hydroxyl, alkoxy, cyano, ester, carboxylic acid, substituted or unsubstituted amino group, and n is 1 to 4;

[0103] in,

[0104] In equation (III),

[0105] R1 and R2 are independently hydrogen, branched or straight-chain C1–C8 alkyl, substituted or unsubstituted aryl, heteroaryl or aralkyl;

[0106] R3 is a branched or straight-chain C1–C4 alkyl or heteroalkyl or C4–C8 alkyl or heteroalkyl, or a substituted or unsubstituted aryl group;

[0107] X is NR5, where R5 is C 2-8 alkenyl, C 2-8 alkynyl or aralkyl;

[0108] Y is selected from C(H)R4 or NR5, where R4 and R5 are independently hydrogen, branched or straight-chain C. 1-8 Alkyl or heteroalkyl, alkenyl or C2–C8 alkynyl, aralkyl, and wherein the compounds having formula (I), formula (II) or formula (III) are substantially pure (-)-enantiomers, substantially pure (+)-enantiomers, or racemic mixtures of (-)-enantiomers and (+)-enantiomers, or pharmaceutically acceptable salts thereof;

[0109] Effective amounts of compounds that are antihypertensive drugs (such as alpha-adrenergic blockers); and

[0110] At least one pharmaceutically acceptable excipient. In some preferred embodiments, the compound of formula (III) is a substantially pure (-)-enantiomer. In some embodiments, the compound is buntanetap: .

[0111] In some embodiments, the antihypertensive drug is terazosin or a pharmaceutically acceptable salt thereof, administered orally once daily in amounts less than about 0.8 mg, less than about 0.7 mg, or less than about 0.6 mg, and buntanetap is administered orally once daily in amounts of about 2 mg to about 80 mg, about 3 mg to about 60 mg, about 5 mg to about 30 mg, about 7.5 mg to about 30 mg, about 10 mg to about 30 mg, or about 15 mg to about 30 mg.

[0112] In some embodiments, the antihypertensive drug is doxazosin or a pharmaceutically acceptable salt thereof, administered orally once daily in amounts less than about 0.8 mg, less than about 0.7 mg, or less than about 0.6 mg, and buntanetap is administered orally once daily in amounts of about 2 mg to about 80 mg, about 3 mg to about 60 mg, about 5 mg to about 30 mg, about 7.5 mg to about 30 mg, about 10 mg to about 30 mg, or about 15 mg to about 30 mg.

[0113] In some embodiments, the antihypertensive drug is alfuzosin or a pharmaceutically acceptable salt thereof, administered orally once daily in amounts of less than about 7 mg, less than about 6 mg, or less than about 5 mg, and buntanetap is administered orally once daily in amounts of about 2 mg to about 80 mg, about 3 mg to about 60 mg, about 5 mg to about 30 mg, about 7.5 mg to about 30 mg, about 10 mg to about 30 mg, or about 15 mg to about 30 mg.

[0114] definition

[0115] As used in this article, each of the following terms has the meaning that is relevant to it in this section.

[0116] Unless otherwise defined, all technical and scientific terms used herein generally have the same meaning as commonly understood by one of ordinary skill in the art to which this invention pertains. Typically, the nomenclature and laboratory procedures used herein in biochemistry, analytical chemistry, and organic chemistry are those well-known and commonly used in the art. Standard techniques or modifications thereof are used in chemical synthesis and chemical analysis.

[0117] This article uses the articles “a” and “an” to refer to one or more (i.e., at least one) grammatical objects of the article. For example, “element” means one or more elements.

[0118] The term "about" will be understood by those skilled in the art and will vary to some extent depending on the context in which it is used. In the context of this application, the term "about" means a value within 20% (± 20%) of the value immediately following the term "about," including values ​​equal to the upper limit of that range (i.e., +20%) and values ​​equal to the lower limit of that range (i.e., -20%). For example, the phrase "about 100" covers any value between 80 and 120, including both 80 and 120.

[0119] The terms “blood pressure medication”, “antihypertensive drug”, “vasodilator”, and “antihypertensive drug” are considered synonyms for the purposes of the invention described herein and include drugs capable of lowering human blood pressure as well as agonists and antagonists of adrenergic receptors.

[0120] As used herein, the terms “buntanetap” and “Posiphen” are used interchangeably to refer to (3aR)-1,3a,8-trimethyl-1,2,3,3a,8,8a-hexahydropyrrolo[2,3-b]indole-5-ylphenylcarbamate or a salt thereof.

[0121] As used in this article, the term "APP" refers to amyloid precursor protein.

[0122] As used herein, the term "Aβ" refers to Abeta or amyloid β or amyloid β peptide. For the purposes of this invention, these terms are considered synonyms.

[0123] For the purposes of this invention, “buntanetap-type” drugs or “compounds similar to buntanetap described herein” encompass formulas (I), (II), (III), or (IV).

[0124] As used in this article, the term "HTT" refers to huntingtin or huntingington protein.

[0125] As used in this article, "TDP43" refers to the TAR-DNA binding protein TDP43.

[0126] As used in this article, “C9orf72” refers to the C9orf72 protein found in many brain regions.

[0127] As used herein, the term "neurotoxic aggregate" refers to a protein or family of proteins that have neurotoxic effects when accumulated in brain tissue, such as brain tissue. Non-limiting examples of neurotoxic aggregates include APP, Aβ, SOD1, SNCA, NAC, TSE amyloid plaques, HTT, Tau, TDP43, and C9orf72.

[0128] As used herein, the terms “protein,” “peptide,” and “polypeptide” are used interchangeably to refer to compounds composed of amino acid residues covalently linked by peptide bonds.

[0129] As used in this article, the term “specific binding” refers to a molecule, such as an antibody or small molecule, that recognizes and binds to another molecule or feature, but does not substantially recognize or bind to other molecules or features in the sample.

[0130] As used herein, the term “inhibition” means reducing or completely preventing the expression, stability, function, or activity of molecules, reactions, interactions, genes, mRNAs, and / or proteins by a measurable amount. Inhibitors are compounds, such as antagonists, that bind to, partially or completely block, reduce, prevent, delay, inactivate, desensitize, or downregulate the stability, expression, function, and activity of proteins, genes, and mRNAs.

[0131] Depending on the disease being treated, the “therapeutic effect” provided by the method of the present invention includes, for example, an improvement in mental function as determined by changes in scores on a mental function assessment scale; a reduction in hypertension, a reduction in nocturia, an improvement in sexual function, a reduction in total plasma Tau levels; a reduction in amyloid β (Aβ) production; a reduction in tau production; a reduction in α-synuclein (αSYN) production; a reduction in TDP43 production; and a combination of two or more of the above.

[0132] In the context of this invention, “improvement in mental function” can be determined by changes in scores on tests known to those skilled in the art, including, for example, Alzheimer’s Disease Assessment Scale-Cognitive Subscales (e.g., “ADAS-Cog 11”, “ADAS-Cog 12”, “ADAS-Cog 13”, “ASAS-Cog 14”), Mini-Mental State Examination (MMSE), Montreal Cognitive Assessment (MoCA), and Wechsler Intelligence Scale, compared with scores at the start of administration (used as baseline) 3 months after administration.

[0133] In the context of this invention, improvements in motor function can be determined by tests known to those skilled in the art, including, for example, the MDS Unified Parkinson's Disease Rating Scale (MDS-UPDRS).

[0134] The terms "effective amount" or "therapeutic effective amount" are used interchangeably herein to refer to the amount of a compound, formulation, material, or composition as described herein that effectively achieves a particular biological outcome. Such outcomes may include, but are not limited to, treatment of a disease or condition as determined in any suitable manner in the art.

[0135] As used herein, the term "pharmaceutical composition" refers to a mixture of at least one compound of the present invention with other chemical components such as carriers, stabilizers, diluents, dispersants, suspending agents, thickeners, and / or excipients. The pharmaceutical composition facilitates the administration of the compound to a living organism. Various techniques for administering compounds exist in the art, including but not limited to intravenous, oral, aerosol, parenteral, ophthalmic, pulmonary, and topical administration.

[0136] As used herein, the term “combined administration” refers to the administration of compounds of formulas (I), (II), (III), and / or (IV) together with a suitable vasodilator or antihypertensive agent (e.g., an alpha-adrenergic blocker) to a mammal (e.g., a human subject or human patient) such that the two classes of agents provide overlapping effects. While these two classes of agents may be administered in single dosage forms in certain circumstances, given their different physical / chemical properties (including, but not limited to, solubility, bioavailability, half-life, metabolism, and clearance / elimination from the body), it is anticipated that these agents may be administered separately via the same or different routes of administration to achieve overlapping effects.

[0137] "Pharmaceutical acceptable" means material that is compatible with the activity of compounds useful in this invention and is physiologically acceptable to patients (e.g., humans) from a pharmacological / toxicological perspective and is acceptable to manufacturing medicinal chemists from a physical / chemical perspective regarding composition, formulation, stability, patient acceptability, and bioavailability.

[0138] "Pharmaceutically acceptable carrier" refers to a pharmaceutically acceptable material, composition, or carrier, such as a liquid or solid filler, stabilizer, dispersant, suspending agent, diluent, excipient, thickener, solvent, or encapsulating material, that participates in the carrying or transport of the compound useful in this invention within or to a patient, enabling it to perform its intended function. Typically, such constructs carry or transport from one organ or body site to another. Each carrier must be "acceptable" in the sense of compatibility with other components of the formulation, including the compound useful in this invention, and harmless to the patient. Some examples of materials that can be used as pharmaceutically acceptable carriers include: sugars such as lactose, glucose, and sucrose; starches such as corn starch and potato starch; cellulose and its derivatives such as sodium carboxymethyl cellulose, ethyl cellulose, and cellulose acetate; powdered tragacanth gum; malt; gelatin; talc; excipients such as cocoa butter and suppository waxes; oils such as peanut oil, cottonseed oil, safflower oil, sesame oil, olive oil, corn oil, and soybean oil; glycols such as propylene glycol; polyols such as glycerol, sorbitol, mannitol, and polyethylene glycol; esters such as ethyl oleate and ethyl laurate; agar; buffers such as magnesium hydroxide and aluminum hydroxide; surfactants; alginic acid; pyrogen-free water; isotonic saline; Ringer's solution; ethanol; phosphate buffer solutions; and other non-toxic compatible substances used in pharmaceutical formulations. As used herein, "pharmaceuticalally acceptable carrier" also includes any and all coatings, antibacterial and antifungal agents, and absorption delay agents that are compatible with the activity of the useful compounds of the present invention and are physiologically acceptable to patients. Additional active compounds may also be incorporated into the composition. "Pharmaceuticalally acceptable carrier" may further include pharmaceutically acceptable salts of the compounds useful in the present invention. Other additional ingredients that may be included in pharmaceutical compositions used to carry out the present invention are known in the art and described, for example, in Remington's Pharmaceutical Sciences (Genaro, Ed., Mack Publishing Co., 1985, Easton, PA), which is incorporated herein by reference.

[0139] As used herein, the term "salt" encompasses the addition salt of a free acid or free base that is a compound useful in this invention. Suitable acid addition salts can be prepared from inorganic or organic acids. Examples of inorganic acids include hydrochloric acid, hydrobromic acid, hydroiodic acid, nitric acid, carbonic acid, sulfuric acid, phosphoric acid, perchloric acid, and tetrafluoroboric acid. Suitable organic acids can be selected from aliphatic, cycloaliphatic, aromatic, aryliphatic, heterocyclic, carboxylic, and sulfonic acid organic acids, examples of which include formic acid, acetic acid, propionic acid, succinic acid, glycolic acid, gluconic acid, lactic acid, malic acid, tartaric acid, citric acid, ascorbic acid, glucuronic acid, maleic acid, fumaric acid, pyruvic acid, aspartic acid, glutamic acid, benzoic acid, anthranilic acid, 4-hydroxybenzoic acid, phenylacetic acid, mandelic acid, bis(hydroxynaphthyl) acid (embolic acid), methanesulfonic acid, ethanesulfonic acid, benzenesulfonic acid, pantothenic acid, trifluoromethanesulfonic acid, 2-hydroxyethanesulfonic acid, p-toluenesulfonic acid, aminobenzenesulfonic acid, cyclohexylsulfamic acid, stearic acid, alginic acid, β-hydroxybutyric acid, salicylic acid, galactobionic acid, and galacturonic acid. Suitable base addition salts of the compounds useful in this invention include, for example, metal salts, including alkali metals, alkaline earth metals, and transition metal salts, such as, for example, lithium, calcium, magnesium, potassium, sodium, and zinc salts. Acceptable base addition salts also include organic salts made from basic amines, such as, for example, N,N'-dibenzylethylenediamine, chloroprocaine, choline, diethanolamine, ethylenediamine, meglumine (N-methylglucosamine), and procaine. All these salts can be prepared by conventional means from the corresponding free base compounds, for example, by reacting a suitable acid or base with the corresponding free base.

[0140] As used herein, the terms “individual,” “patient,” or “subject” include members of any animal species, including but not limited to birds, humans, and other primates, as well as other mammals, including commercially relevant mammals such as cattle, pigs, horses, sheep, cats, and dogs. Preferably, the subject is a human.

[0141] The term neurological disease or disorder is intended to include Alzheimer's disease, tau protein disease, Parkinson's disease and alpha-synucleinosis, prions, Down syndrome, Huntington's disease, amyotrophic lateral sclerosis, multiple sclerosis, and other dementias and neurodegenerative diseases.

[0142] As used in this article, the term "synergistic" means that each drug, when administered alone (i.e., the dosage), is ineffective and subtherapeutic as a single therapy, but is therapeutic when administered in combination.

[0143] As used herein, the terms “treatment” or “manipulation” mean reducing the frequency of a subject’s experience of symptoms, or administering a combination of agents or compounds to reduce the frequency and / or severity of experienced symptoms. As used herein, “relief” and the term “treatment” are used interchangeably. Treating a disease, disorder, or condition may or may not include the complete eradication or elimination of symptoms. Therefore, the term “treatment” encompasses the prevention and mitigation of the conditions described herein.

[0144] As used herein, the term “therapeutic” means the treatment and / or prevention of the symptoms or disease states described herein.

[0145] As used herein, the term "alkyl" refers to a branched or unbranched saturated hydrocarbon group with 1 to 4, 1 to 8, or 1 to 20 carbon atoms, such as methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, tert-butyl, pentyl, hexyl, heptyl, octyl, etc. Examples of cycloalkyl groups include cyclopentyl and cyclohexyl.

[0146] As used herein, the term "alkenyl" refers to a hydrocarbon group with 2 to 4, 2 to 8, or 2 to 20 carbon atoms and a structural formula containing a carbon-carbon double bond.

[0147] As used herein, the term "alkynyl" refers to a hydrocarbon group with 2 to 4, 2 to 8, or 2 to 20 carbon atoms and a structural formula containing a carbon-carbon triple bond.

[0148] The term "aryl" is defined as any carbon-based aromatic group, including but not limited to phenyl, benzene, naphthalene, anthracene, phenanthrene, pyrene, and benzo[a]pyrene.

[0149] The term "substituted aryl" is defined as an aryl group having at least one non-hydrogen group attached to the aryl group. Examples of groups that can be attached to the aryl group include, but are not limited to, alkyl, alkynyl, alkenyl, aryl, heterocyclic, halogen, nitro, amino, ester, ketone, aldehyde, hydroxy, carboxylic acid, alkoxy, cyano, alkoxy, thioalkyl, haloalkyl, hydroxyalkyl, alkylamino, dialkylamino, or acyl. In various embodiments, the substituent is bonded to carbon 2, 3, 4, 5, or 6 of one of these moieties. Examples of alkoxy substituents include, but are not limited to, methoxy, ethoxy, and isopropoxy. Examples of acyl substituents include acetyl and benzoyl.

[0150] The term "aralkyl" is defined as an aryl group having an alkyl, ynyl, or alkenyl group attached to an aryl group. An example of an aralkyl group is a benzyl group.

[0151] The term "heteroaryl" is defined as an aryl group having at least one heteroatom, such as nitrogen, sulfur, or oxygen, incorporated into the aryl ring.

[0152] The term "heteroalkyl" is defined as an alkyl group having at least one heteroatom, such as nitrogen, sulfur, oxygen, or phosphate ester, incorporated into or attached to an alkyl group. Attached Figure Description

[0153] Figure 1 This is a Western blot and image showing that buntanetap reduces APP in vitro in a dose-dependent manner in SH-SY-5Y human neuroblastoma cells.

[0154] Figure 2AThe results showed that buntanetap treatment in APP / PS1 transgenic AD mice reduced the levels of APP and its fragments in the hippocampus, as demonstrated by tables, graphs, and Western blots.

[0155] Figure 2A The results showed that buntanetap treatment in APP / PS1 transgenic AD mice reduced the levels of APP and its fragments in the hippocampus, as demonstrated by tables, graphs, and Western blots.

[0156] Figure 2B It showed a dose-dependent improvement in cognition in people diagnosed with early-stage AD.

[0157] Figure 2C The efficacy of buntanetap was shown to be strongly correlated with MMSE status.

[0158] Figure 3 This is a table showing the reduction of APP / Abeta, tau / phosphorylated tau, and α-synuclein in the cerebrospinal fluid of patients with mild cognitive impairment. Detailed Implementation

[0159] This invention relates in part to a method of inhibiting, preventing, or treating neurodegenerative diseases such as Alzheimer's disease, Lewy body dementia, frontotemporal dementia, other dementias, chronic traumatic encephalopathy, tau proteinopathy, Parkinson's disease, alpha-synucleinopathy, prions, Down syndrome, Huntington's disease, amyotrophic lateral sclerosis, multiple sclerosis, and other neurodegenerative diseases characterized by protein misfolding, aggregation, and accumulation in the brain leading to inflammation and ultimately cell death; and hypertension, by administering buntanetap, compounds similar to buntanetap described herein (e.g., medicaments covering formulas (I), (II), (III), or (IV)), their pharmaceutically acceptable salts and complexes, and antihypertensive drugs (e.g., alpha-adrenergic blockers), and one or more pharmaceutically acceptable excipients.

[0160] Buntanetap is a selective inhibitor of amyloid precursor protein (APP) production and has potential use as a treatment modifier for Alzheimer's disease (Cullen 2006; Utsuki 2006; Lahiri 2007). Buntanetap was discovered at the National Institute on Aging in the United States and was selected from a series of structurally related compounds designed specifically for APP and possessing little or no acetylcholinesterase inhibitory activity. In relevant preclinical in vitro and in vivo studies, buntanetap has been shown to reduce APP and thus reduce the production of β-amyloid protein (Aβ). Maccecchini et al., “Buntanetap as a Candidate Drug to Lower CSF Amyloid Precursor Protein, Amyloid-β Peptide and τ Levels: Target Engagement, Tolerability and Pharmacokinetics in Humans,” J. Neurosurg. Psychiatry 2012;83:894-902, which is incorporated herein by reference, reported the results of a phase 1 randomized, double-blind, placebo-controlled safety, tolerability, and pharmacokinetic study of buntanetap in 120 healthy human volunteers using single and multiple escalation doses to determine the dose for subsequent use in a small, non-randomized study in 5 MCI subjects. Buntanetap doses up to 4 x 60 mg x 10 days were well tolerated. In plasma, buntanetap was rapidly absorbed at all doses (Tmax = 1.2 to 1.7 h) and cleared from circulation in a biphasic manner (terminal half-life 4.3–4.7 h). Buntanetap was shown to be well tolerated and significantly reduced the levels of sAPPα, sAPPβ, t-tau, p-tau, and specific inflammatory markers in CSF, and also showed a reduction in CSF Aβ. 42The activity of buntanetap is also described in the applicant's U.S. Patent No. 10,383,851, which is incorporated herein by reference. Phase II data for buntanetap have been published in C. Fang et al., Buntanetap, a Novel Translational Inhibitor of Multiple Neurotoxic Proteins, Proves to Be Safe and Promising in Both Alzheimer's and Parkinson's Patients, J Prev Alzheimers Dis (2022). https: / / doi.org / 10.14283 / jpad.2022.84, published on October 10, 2022, the entire contents of which are incorporated herein by reference. This publication reports the results of a Phase 2a clinical study, a double-blind, placebo-controlled, multicenter study of 14 patients with early-stage Alzheimer's disease (AD) and 54 patients with early-stage Parkinson's disease (PD). AD patients were given 80 mg of buntanetap or placebo once daily. Patients with PD were given 5 mg, 10 mg, 20 mg, 40 mg, or 80 mg of buntanetap or placebo via QD. The primary endpoint was safety and tolerability; the secondary endpoint was the pharmacokinetics of buntanetap in plasma. In both AD and PD patients, buntanetap was well tolerated and safe up to 80 mg. Cmax and AUC increased with increasing dose, with no evidence of a plateau up to 80 mg QD. Biomarker data showed a trend toward reduced levels of neurotoxic proteins and inflammatory factors, as well as improved axonal integrity and synaptic function in both the AD and PD cohorts. Psychometric tests showed statistically significant improvements in AD patients' ADAS-Cog11 and WAIS codes, and in PD patients' MDS-UPDRS and WAIS codes.

[0161] Buntanetap, developed by QR Pharma, Inc. (now Annovis Bio, Inc.) ®Buntanetap is a small molecule that reduces soluble APP protein levels through a posttranscriptional mechanism. It is also known as (+)-phenserine. Buntanetap is a stereoisomer of (-)-phenserine ((-)-N-phenylcarbamoylphysostigmine), which has been clinically evaluated as an anticholinesterase inhibitor for Alzheimer's disease. Phenserine, an AChE inhibitor, was investigated as a potential treatment for age-related and Alzheimer's disease-associated cognitive impairment (US Patent No. 5,409,948). Due to its high cholinergic side effects, phenserine failed in three phase 3 clinical trials.

[0162] As used herein, the term "buntanetap" refers to (3aR)-1,3a,8-trimethyl-1,2,3,3a,8,8a-hexahydropyrrolo[2,3-b]indole-5-ylphenylcarbamate, having the chemical structure shown in Formula IV below, and a chemical purity of at least 90%, preferably at least 95%, at least 98%, at least 99%, at least 99.5%, at least 99.9%, or 100%, with the following chemical structure: (IV).

[0163] When applied to pharmaceutically acceptable salts of (3aR)-1,3a,8-trimethyl-1,2,3,3a,8,8a-hexahydropyrrolo[2,3-b]indole-5-ylphenylcarbamate or buntanetap, the term "chemical purity" refers to the weight percentage of pharmaceutically acceptable salts of (3aR)-1,3a,8-trimethyl-1,2,3,3a,8,8a-hexahydropyrrolo[2,3-b]indole-5-ylphenylcarbamate or buntanetap, plus any other chemical impurities that may be present (e.g., their (-)-enantiomers).

[0164] This invention also covers the active metabolites of buntanetap. These active metabolites have been previously identified and, for example, include "N..." 1 -nor-buntanetap (which refers to (3aR)-3a,8-dimethyl-1,2,3,3a,8,8a-hexahydropyrrolo[2,3-b]indole-5-ylphenylcarbamate) or a salt thereof; "N 8-nor-buntanetap (which refers to (3aR)-1,3a-dimethyl-1,2,3,3a,8,8a-hexahydropyrrolo[2,3-b]indole-5-ylphenylcarbamate) or a salt thereof; and "N 1 N 8 -nor-buntanetap (which refers to (3aR)-3a-methyl-1,2,3,3a,8,8a-hexahydropyrrolo[2,3-b]indole-5-ylphenylcarbamate) or its salts.

[0165] In other embodiments, the methods of the present invention are implemented using phenserine or phenserine-like compounds, metabolites, enantiomers or derivatives thereof known to those skilled in the art, such as those described in U.S. Patent Nos. 5,171,750; 6,410,747; 6,683,105, 7,153,882; 7,786,162; 7,973,057; 8,258,172; 8,546,430; 8,691,864; and 8,853,253, all of which are incorporated herein by reference in their entirety.

[0166] In a broader sense, this invention relates in part to the combined administration of a buntanetap-type compound as defined by formula (I), formula (II), formula (III) or formula (IV) with an antihypertensive drug.

[0167] The buntanetap type compounds include compounds having the following formula I or II:

[0168] Where R1 and R2 are independently hydrogen, branched or straight-chain C. 1- R3 is a C8 alkyl, substituted or unsubstituted aryl, heteroaryl or aralkyl; R3 is a branched or straight-chain C1-C4 alkyl or heteroaryl or C4-C8 alkyl or heteroaryl, or a substituted or unsubstituted aryl; X and Y are independently O, S, alkyl, hydrocarbon moiety, C(H)R4 or NR5, wherein R4 and R5 are independently hydrogen, oxygen, branched or straight-chain C1-C8 alkyl, C2-C8 alkenyl or C2-C8 ynyl, aralkyl, or a substituted or unsubstituted aryl; and R6 is hydrogen; C1-C8 alkyl, C1-C8 alkenyl, C2-C8 ynyl, aralkyl, or a substituted or unsubstituted aryl, or (CH2). n R7, wherein R7 is a hydroxyl, alkoxy, cyano, ester, carboxylic acid, substituted or unsubstituted amino group, and n is 1 to 4, and an effective amount of an antihypertensive drug.

[0169] The chiral center of compounds of formula I and II is a carbon atom bonded with R3. As depicted herein, the R3 of the (+)-enantiomer points behind the page plane. Although only the (+)-isomer is illustrated for space-saving purposes, in other embodiments, compounds having formula I or II can be (+)-isomers, (-)-isomers, and mixtures of the two isomers (e.g., racemic mixtures, including 1:1 racemic mixtures) of all compounds covered by this invention.

[0170] In some embodiments, the enantiomeric purity of the (+)-enantiomer of the compound having formula I or II is 55% to 100%, preferably 75% to 100%, more preferably 85% to 100%, more preferably 95% to 100%, and even more preferably 100%.

[0171] In some preferred embodiments, the compounds having formula I or II are substantially pure (+)-enantiomers.

[0172] In one embodiment, when the compound is of formula I, R3 is methyl and X is NCH3.

[0173] In one embodiment, when the compound is of formula I or II, R3 is not methyl. In a particular embodiment, R3 is a branched or straight-chain alkyl or heteroalkyl group with 2, 3, 4, 5, 6, 7, or 8 carbons, or a substituted or unsubstituted aryl group.

[0174] In another embodiment, when the compound is of formula I or II, Y is C(H)R4 or X is O, S or C(H)R4.

[0175] In another embodiment, when the compound is of formula I, R3 is methyl, X is NCH3, and Y is NCH3. In one embodiment, when the compound is of formula I, R3 is methyl, X is NCH3, Y is NCH3, R1 is a C1-C8 straight-chain alkyl or benzyl, and R2 is hydrogen. In one embodiment, when the compound is of formula I, R3 is methyl, X is NCH3, Y is NCH3, R1 is a substituted or unsubstituted phenyl, and R2 is hydrogen. In one embodiment, when the compound is of formula I, R3 is methyl, X is NCH3, Y is NCH3, and R1 and R2 are independently methyl or ethyl.

[0176] In another embodiment, when the compound is of formula I, R3 is methyl, X is NCH3, and Y is O. In one embodiment, when the compound is of formula I, R3 is methyl, X is NCH3, Y is O, R1 is a C1-C8 straight-chain alkyl or benzyl, and R2 is hydrogen. In one embodiment, when the compound is of formula I, R3 is methyl, X is NCH3, Y is O, and R1 and R2 are independently methyl or ethyl. In one embodiment, when the compound is of formula I, R3 is methyl, X is NCH3, Y is O, R1 is a substituted or unsubstituted phenyl group, and R2 is hydrogen.

[0177] In another embodiment, when the compound is of formula I, R3 is methyl, X is NCH3, and Y is S. In one embodiment, when the compound is of formula I, R3 is methyl, X is NCH3, Y is S, R1 is a C1-C8 straight-chain alkyl or benzyl, and R2 is hydrogen. In one embodiment, when the compound is of formula I, R3 is methyl, X is NCH3, Y is S, and R1 and R2 are independently methyl or ethyl. In one embodiment, when the compound is of formula I, R3 is methyl, X is NCH3, Y is S, R1 is a substituted or unsubstituted phenyl, and R2 is hydrogen.

[0178] In another embodiment, when the compound is of formula I, R3 is methyl, X is NCH3, and Y is NR5. In one embodiment, when the compound is of formula I, R3 is methyl, X is NCH3, and Y is NR5, wherein R5 is –CH2CH=CH2, –CH2CH2Ph, benzyl, or hydrogen.

[0179] In another embodiment, when the compound has Formula I, R3 is methyl, Y is NCH3, and X is NCH3, wherein R4 is benzyl or hydrogen.

[0180] In another embodiment, when the compound is of formula I, R3 is methyl, X is NCH3, Y is NR5, wherein R4 and R5 are each independently hydrogen or benzyl.

[0181] In another embodiment, when the compound is of formula I, R3 is phenyl, X is NCH3, and Y is NCH3.

[0182] In another embodiment, when the compound is of formula I, R3 is methyl, X is NCH3, and Y is not NH or NHCH2Ph.

[0183] In some embodiments, when the compound is of formula I, R1 and R2 are independently hydrogen, substituted or unsubstituted aryl groups, R3 is a straight-chain C1-C8 alkyl group, and X and Y are independently NR5, wherein R5 is independently hydrogen or a straight-chain C1-C8 group.

[0184] In some embodiments, when the compound is of formula I, R1 and R2 are independently hydrogen or unsubstituted aryl groups, R3 is a straight-chain C1-C8 alkyl group, and X and Y are independently NR5, wherein R5 is independently hydrogen or a straight-chain C1-C8 group.

[0185] In some embodiments, when the compound is of formula I, R1 is hydrogen, R2 is an unsubstituted aryl group, R3 is methyl, and X and Y are independently NR5, wherein R5 is independently hydrogen or methyl.

[0186] In a preferred embodiment, when the compound is of formula I, R1 is hydrogen, R2 is phenyl, R3 is methyl, X is NCH3, and Y is NCH3.

[0187] In another embodiment, when the compound is of formula I, R1 is hydrogen, R2 is phenyl, R3 is methyl, X is NCH3, and Y is NH.

[0188] In a preferred embodiment, when the compound is of formula I, R1 is hydrogen, R2 is phenyl, R3 is methyl, X is NH, and Y is NCH3.

[0189] In a preferred embodiment, when the compound is of formula I, R1 is hydrogen, R2 is phenyl, R3 is methyl, X is NH, and Y is NH.

[0190] In another embodiment, when the compound is of formula II, R3 is methyl, X is C(H)CH3, and R6 is (CH2)2R7, wherein R7 is a substituted or unsubstituted amino group.

[0191] In a preferred embodiment, when the compound is of formula II, R3 is methyl, X is NCH3, and R6 is (CH2)2R7, wherein R7 is a substituted or unsubstituted amino group.

[0192] In a preferred embodiment, the compound having formula II is a substantially pure (+)-enantiomer.

[0193] The present invention also relates to the use of compounds having the following formula (III): (III)

[0194] R1 and R2 are independently hydrogen, branched or straight-chain C1–C8 alkyl, substituted or unsubstituted aryl, heteroaryl, or arylalkyl; R3 is a branched or straight-chain C1–C4 alkyl or heteroaryl, or C4–C8 alkyl or heteroaryl, or a substituted or unsubstituted aryl; X is NR5, where R5 is C 2-8 alkenyl, C 2-8 Alkyne or aralkyl, and Y is selected from C(H)R4 or NR5, wherein R4 and R5 are independently hydrogen, branched or straight-chain C 1-8 Alkyl or heteroalkyl, alkenyl or C2–C8 ynyl, aralkyl.

[0195] As depicted herein, the R3 of the (-)-enantiomer points forward of the page plane. Although only the (-)-isomer is illustrated for space-saving purposes, in other embodiments, the compound having formula (III) can be the (+)-isomer, (-)-isomer, and mixture of the two isomers (e.g., racemic mixtures, including 1:1 racemic mixtures) of all compounds covered by this invention.

[0196] In a preferred embodiment, the compound having formula (III) is a substantially pure (-)-enantiomer.

[0197] In one embodiment, when the compound is of formula (III), X is NR5, where R5 is an aralkyl group.

[0198] In one embodiment, when the compound is of formula (III), X and Y are NR5, wherein R5 is an aralkyl group.

[0199] In one embodiment, when the compound is of formula (III), X is NR5, R5 is an aralkyl group, and Y is NR5, where R5 is a branched or straight-chain C. 1-8 Alkyl or heteroalkyl.

[0200] In one embodiment, when the compound is of formula (III), R1 is a branched or straight-chain C1–C8 alkyl, aralkyl, or aryl; R2 is hydrogen, a branched or straight-chain C1–C8 alkyl, a substituted or unsubstituted aryl or aralkyl; Y is NR5, wherein R5 is an aralkyl; and X is NR5, wherein R5 is hydrogen, a branched or straight-chain C1–C8 alkyl, or a substituted or unsubstituted aryl or aralkyl. 1-8 Alkyl or heteroalkyl.

[0201] In one embodiment, when the compound is of formula (III), R1 is a branched or straight-chain C1–C8 alkyl, aralkyl, or aryl; R2 is hydrogen, branched or straight-chain C1–C8 alkyl; Y is NR5, wherein R5 is benzyl; and X is NR5, wherein R5 is hydrogen, branched or straight-chain C1–C8 alkyl. 1-8 Alkyl or heteroalkyl.

[0202] In one embodiment, when the compound is of formula (III), R1 is a branched or straight-chain C1–C8 alkyl, aralkyl, or aryl; R2 is hydrogen, a branched or straight-chain C1–C8 alkyl; Y is NR5, wherein R5 is benzyl; and X is NR5, wherein R5 is hydrogen.

[0203] In one embodiment, when the compound is of formula (III), R1 is p-halophenyl; Y is NCH3; and X is NR5, wherein R5 is alkyl or aralkyl, and wherein when R5 is benzyl, R1 is not p-bromophenyl.

[0204] In one embodiment, when the compound is of formula (III), R1 is p-isopropylphenyl; R2 is hydrogen; R3 is methyl; Y is NR5, wherein R5 is benzyl; and X is NR5, wherein R5 is hydrogen.

[0205] The formulations of this invention cover (+)-isomers, (-)-isomers, and mixtures of two isomers (e.g., racemic 1:1 mixtures) of all compounds of this invention, unless such compounds are explicitly excluded.

[0206] Unless otherwise stated, the variables throughout this application, such as R1-R7, n, X, and Y, are the same as those previously defined.

[0207] The compounds described herein can form salts with acids or bases, and such salts are included in this invention. In one embodiment, the salt is a pharmaceutically acceptable salt. The term "salt" encompasses the addition salt of a free acid or free base that is a compound of this invention. The term "pharmaceutically acceptable salt" refers to a salt having toxicity characteristics within the range that provide utility in pharmaceutical applications. Pharmaceutically unacceptable salts may still possess properties such as high crystallinity, which are useful in the practice of this invention, for example, in the synthesis, purification, or formulation of the compounds of this invention.

[0208] Examples of pharmaceutically acceptable salts of Buntanetap include acid addition salts prepared from suitable acids. The suitable acids may be hydrobromic acid, hydrochloric acid, hydroiodic acid, sulfuric acid, carbonic acid, nitric acid, phosphoric acid, tetrafluoroboric acid, perchloric acid, 1-hydroxy-2-naphthoic acid, 2,2-dichloroacetic acid, methanesulfonic acid, trifluoromethanesulfonic acid, 2-hydroxyethanesulfonic acid, benzenesulfonic acid, p-toluenesulfonic acid, cyclohexylaminosulfonic acid, 2-oxoglutaric acid, 4-acetaminobenzoic acid, acetic acid, phenylacetic acid, propionic acid, formic acid, succinic acid, glycolic acid, gluconic acid, malic acid, lactic acid, tartaric acid, citric acid, glucuronic acid, ascorbic acid, maleic acid, fumaric acid, pyruvic acid, aspartic acid, glutamic acid, benzoic acid, 4-hydroxybenzoic acid, anthranilic acid, 4-hydroxybenzoic acid, mandelic acid, dihydroxynaphthoic acid, pantothenic acid, sulfanilic acid, stearic acid, alginic acid, β-hydroxybutyric acid, salicylic acid, galactopyric acid, and galacturonic acid. Preferably, the pharmaceutically acceptable salt is buntanetap tartrate, which is the acid addition salt of tartaric acid.

[0209] Suitable pharmaceutically acceptable base addition salts of the compounds of this invention include, for example, metal salts, including alkali metal salts, alkaline earth metal salts, and transition metal salts, such as, for example, calcium salts, magnesium salts, potassium salts, sodium salts, and zinc salts. Pharmaceutically acceptable base addition salts also include organic salts made from basic amines, such as, for example, N,N'-dibenzylethylenediamine, chloroprocaine, choline, diethanolamine, ethylenediamine, meglumine (N-methylglucosamine), and procaine. Examples of pharmaceutically unacceptable base addition salts include lithium salts and cyanates. All these salts can be prepared from the respective compounds, for example, by reacting them with a suitable acid or base.

[0210] In some preferred embodiments, the (buntanetap) compound of the present invention is administered in combination with an antihypertensive drug or a vasodilator. Part of the physiological process of vasodilation involves the release of nitric oxide from vascular endothelial cells, which subsequently diffuses to nearby vascular smooth muscle cells. There, nitric oxide activates soluble guanylate cyclase, which converts guanosine triphosphate (GTP) to cyclic guanosine monophosphate (cGMP), the main effector of the system.

[0211] Hypertension is one of the major modifiable risk factors for Alzheimer's disease and related dementia (ADRD). See, e.g., Yasar, S. et al. “Antihypertensive Drugs Decrease Risk of AlzheimerDisease, Neurology. 2013 Sep 3; 81(10): 896–903. doi: 10.1212 / WNL.0b013e3182a35228; Livingston G, Huntley J, Sommerlad A, et al. Dementiaprevention, intervention, and care: 2020 report of the Lancet Commission. Lancet. 2020;396(10248):413-446. doi:10.1016 / S0140-6736(20)30367-6; National Academies of Sciences, Engineering, and Medicine. Preventing Cognitive Decline and Dementia: A Way Forward. National Academies Press; 2017. KehoePG. The coming of age of the angiotensin hypothesis in Alzheimer's disease: progress toward disease prevention and treatment? J Alzheimers Dis. 2018;62(3):1443-1466. doi:10.3233 / JAD-171119. Mechanistic, observational, and randomized clinical studies have shown that certain classes of antihypertensive drugs can reduce cognitive impairment in addition to their blood pressure-lowering effects. Kehoe PG. The coming of age of the angiotensin hypothesis in Alzheimer's disease: progress toward disease prevention and treatment? J Alzheimers Dis.2018;62(3):1443-1466. doi:10.3233 / JAD-171119.3233 / JAD-171119; Levi Marpillat N, Macquin-Mavier I, Tropeano A-I, Bachoud-Levi A-C, Maison P. Antihypertensive classes,cognitive decline, and incidence of dementia: a network meta-analysis. JHypertens. 2013;31(6):1073-1082 doi:10.1097 / HJH.0b013e3283603f53; den BrokMGHE, van Dalen JW, Abdulrahman H, et al. Antihypertensive medication classesand the risk of dementia: a systematic review and network meta-analysis. J AmMed Dir Assoc. 2021;22(7):1386-1395. doi:10.1016 / j.jamda.2020.12.019; HajjarI, Okafor M, McDaniel D, et al. Effects of candesartan vs lisinopril onneurocognitive function in older adults with executive mild cognitiveimpairment: a randomized clinical trial. JAMA Netw Open. 2020;3(8):e2012252.doi:10.1001 / jamanetworkopen.2020.12252; ClinicalTrials.gov. Risk Reductionfor Alzheimer’s Disease (rrAD). ClinicalTrials.gov identifier: NCT02913664.Accessed June 19, 2022. https: / / clinicaltrials.gov / ct2 / show / NCT02913664。.

[0212] Previous observational studies have reported that regimens using antihypertensive drugs that stimulate type 2 and type 4 angiotensin II receptors are associated with a lower incidence of new-onset mild cognitive impairment and dementia compared to regimens that do not stimulate type 2 and type 4 angiotensin II receptors. “Association of New Use of Antihypertensives ThatStimulate vs Inhibit Type 2 and 4 Angiotensin II Receptors With Dementia Among Medicare Beneficiaries”, Zachary A. Marcum, PharmD, PhD; Nico Gabriel, MA; Adam P. Bress, PharmD, MS; Inmaculada Hernandez, PharmD, PhD open access JAMA Netw Open. 2023; 6(1):e2249370. doi: 10.1001 / jamanetworkopen.2022.49370. However, according to the Medication Appropriateness Tool for Co-morbid Health Conditions in Dementia (Match-D), Page AT, Potter K, Clifford R, McLachlan AJ, Etherton-Beer C, (October 2016). "Medication appropriatenesstool for co-morbid health conditions in dementia: consensus recommendations from a multidisciplinary expert panel". Internal Medicine Journal. 46 (10):1189–1197. doi:10.1111 / imj.13215. PMC 5129475. PMID 27527376, antihypertensive drugs are usually discontinued in advanced dementia.Furthermore, as Ding, J. et al., in “Antihypertensive Medications and Risk for Incident Dementia and Alzheimer's Disease: a Meta-Analysis of Individual Participant Data From Prospective Cohort Studies” (The Lancet Neurology, Volume 19, Issue 1, pp. 61-70, January 2020), found no evidence in long-term observations that specific classes of antihypertensive drugs were more effective than others in reducing the risk of dementia than other classes. In individuals with hypertension, the use of any such medication is suggested to potentially reduce the risk of dementia.

[0213] There are at least six major classes of antihypertensive drugs: diuretics, beta-blockers, alpha-blockers, calcium channel blockers, renin-angiotensin system inhibitors (including angiotensin-converting enzyme inhibitors), and angiotensin receptor blockers. Antihypertensive drugs include, but are not limited to, thiazide diuretics, ACE (angiotensin-converting enzyme) inhibitors, and calcium channel blockers. Angiotensin II receptor blockers (ARBs) and calcium channel blockers (CCBs) (including dihydropyridine and non-dihydropyridine types), vasodilators, diuretics (including potassium-sparing diuretics, loop diuretics, thiazide diuretics, and thiazide-type diuretics), alpha-blockers, and beta-blockers.

[0214] Calcium channel blockers include, but are not limited to, dihydropyridines, such as amlodipine, barnidipine, cilnidipine, clovidipine, felodipine, isradipine, lercanidipine, levamlodipine, nicardipine, nifedipine, nimodipine, nisoldipine, and nifedipine. Non-dihydropyridine calcium channel blockers include diltiazem and verapamil.

[0215] ACE inhibitors inhibit the activity of angiotensin-converting enzyme (ACE), which is responsible for converting angiotensin I to angiotensin II, a potent vasoconstrictor. These include, but are not limited to, captopril, enalapril, fosinopril, lisinopril, moxipril, perindopril, quinapril, ramipril, trandopril, and benazepril.

[0216] Angiotensin II receptor antagonists (ARBs) work by antagonizing the activation of angiotensin receptors. These agents include, but are not limited to, azilsartan, candesartan, eprosartan, irbesartan, losartan, olmesartan, telmisartan, valsartan, and fimasartan.

[0217] Adrenergic receptor antagonists include, but are not limited to, alpha blockers and beta blockers.

[0218] β-blockers include, but are not limited to, acebutolol, atenolol, bisoprolol, betalolol, carteolol, carvedilol, labetalol, metoprolol, naldolol, nebiolol, oxenolol, pentbuprofenolol, indololol, propranolol, and timolol.

[0219] Vasodilators act directly on the smooth muscle of arteries to relax their walls, allowing blood to flow through them more easily; they are used only in hypertensive emergencies or when other medications are ineffective, and even then, they are rarely given alone. Examples of vasodilators include sodium nitroprusside (a very potent, short-acting vasodilator), hydralazine, and minoxidil.

[0220] Alpha blockers include, but are not limited to, doxazosin, terazosin, chlorpromazine, phentolamine, indolinamine, phenoxybenzamine, prazosin, terazosin, torazoline, and urapidil.

[0221] Mixed α and β blockers include, but are not limited to, bucinolol, carvedilol, labetalol, and clonidine.

[0222] Antihypertensive drugs also include renin inhibitors such as aliskiren and indirect antiadrenergic drugs, including guanethidine, mecamidine, and reserpine.

[0223] Diuretics promote diuresis and include, for example, hydrochlorothiazide and furosemide. Categories of diuretics include thiazides, loop diuretics, potassium-sparing / aldosterone antagonists, vasodilators, centrally acting drugs, and ganglion blockers.

[0224] Thiazide diuretics include, but are not limited to, epithiazide, hydrochlorothiazide, chlorothiazide, benzylfluthiazide, methachlorthiazide, and porbithiazine. Thiazide-like diuretics include, but are not limited to, indapamide, chlorthalidone, metoprazone, sipamide, and clopamide.

[0225] Loop diuretics include, but are not limited to, bumetanide, ethacrynic acid, furosemide, and torasemide.

[0226] Potassium-sparing diuretics include, but are not limited to, amiloride, triamterene, spironolactone, and eplerenone.

[0227] Centrally acting drugs include clonidine and methyldopa.

[0228] Ganglion blockers include imidacloprid.

[0229] Antihypertensive drugs also include aldosterone receptor antagonists such as eplerenone and spironolactone; α2-adrenergic receptor agonists such as clonidine, guanethidine, guanifaxine, methyldopa, and mosonidin; ganglion blockers such as imetifene; potassium-sparing aldosterone antagonists such as amiloride and spironolactone; and endothelin receptor blockers, including but not limited to bosentan (which works by blocking endothelin receptors).

[0230] Dosage and administration

[0231] In the method of the present invention, buntanetap, its analogues, metabolites, or pharmaceutically acceptable salts thereof may be administered parenterally, enterically, or transdermally. Examples of routes of administration for buntanetap, its analogues, metabolites, or pharmaceutically acceptable salts or similar compounds include intravenous, intraocular, intramuscular, subcutaneous, topical, oral, sublingual, and buccal administration. Preferably, for the purposes of the present invention, buntanetap is administered orally.

[0232] In this invention, buntanetap or a pharmaceutically acceptable salt of buntanetap may be administered once, twice, three times, or four times daily. In some embodiments, buntanetap is preferably administered once daily. Depending on the route of administration, buntanetap is administered in different dose ranges.

[0233] In some embodiments, buntanetap or a pharmaceutically acceptable salt of buntanetap is administered orally in an amount of about 0.01 mg to about 120 mg, preferably once daily. In some preferred embodiments, buntanetap or a pharmaceutically acceptable salt of buntanetap is administered in an amount of about 0.01 mg to about 10 mg, about 0.01 mg to about 5 mg, or about 0.01 mg to about 0.9 mg, preferably once daily.

[0234] In some embodiments, the compound is administered according to the formulation and method of the invention to patients who have already exhibited symptoms of a neurological disorder. In other embodiments, the compound is administered according to the formulation and method of the invention to patients who have already exhibited hypertension. In still other embodiments, the compound is administered according to the formulation and method of the invention to patients (human subjects) who have not exhibited any neurological or hypertension problems.

[0235] In certain embodiments of each method of the present invention described above, the oral pharmaceutical composition comprises about 0.01 mg to about 120 mg buntanetap or a pharmaceutically acceptable salt thereof, the IP / IM pharmaceutical composition comprises about 0.03 to about 70 mg buntanetap or a pharmaceutically acceptable salt thereof, and the intravenous (IV) pharmaceutical preparation comprises about 0.1 to about 25 mg buntanetap or a pharmaceutically acceptable salt thereof.

[0236] Generally, the preferred dose of buntanetap for administration to healthy human patients is a tolerable dose, i.e. a dose that does not cause adverse side effects in most human patients. This dose is also effective for preventive treatment of healthy humans for conditions such as neurodegenerative diseases, cancer, cardiovascular homeostasis, diseases or conditions of vital organs, and cardiovascular diseases.

[0237] In some embodiments of the method described herein, the peak plasma circulation level of buntanetap in humans ranges from, for example, from about 0.1 ng / mL to about 40 ng / mL, in some embodiments from about 0.2 ng / mL to about 2 ng / mL, and more preferably from about 0.3 ng / mL to about 12 ng / mL. In some preferred embodiments, the peak plasma circulation level is reached approximately 6 hours after administration of buntanetap to the human body. In some embodiments, the peak plasma circulation level is reached approximately 3 hours after administration of buntanetap to the human body. In some embodiments, following administration of buntanetap to the human body, the plasma circulating level of buntanetap is equal to or greater than about 0.01 ng / mL, 0.05 ng / mL, 0.1 ng / mL, 0.2 ng / mL, 3 ng / mL, 4 ng / mL, 5 ng / mL, 6 ng / mL, 7 ng / mL, 8 ng / mL, 9 ng / mL, 10 ng / mL, 11 ng / mL, 12 ng / mL, 13 ng / mL, 14 mg / mL, 15 ng / mL, 16 ng / mL, 17 ng / mL, 18 ng / mL, 19 ng / mL, or 20 ng / mL after administration. In some embodiments, the half-life of buntanetap in cerebrospinal fluid is about 12 hours after administration, and the half-life of buntanetap in plasma is about 5 hours after administration.

[0238] In the formulations and treatments of the present invention, therapeutic agents used as buntanetap-type drugs and antihypertensive drugs are preferably administered at therapeutically effective amounts known to those skilled in the art. In some embodiments, the therapeutically effective amount is the amount that produces the maximum therapeutic effect. In other embodiments, the therapeutically effective amount produces an effect less than the maximum therapeutic effect. For example, the therapeutically effective amount can be an amount that produces a therapeutic effect while avoiding one or more side effects associated with the dose that produces the maximum therapeutic effect. In other embodiments, the therapeutic amount of the antihypertensive drug (e.g., an alpha-adrenergic blocker) is subtherapeutic (meaning the dose of the antihypertensive drug is below the minimum approved (e.g., approved by a government regulatory agency such as the U.S. FDA) for the treatment of hypertension, or below the dose compared to when the drug is administered without the use of a buntanetap-type drug). Those skilled in the clinical and pharmacological fields will be able to determine the therapeutically effective amount through routine experiments, i.e., by monitoring the subject's response to drug administration and adjusting the dose accordingly. In some embodiments, the antihypertensive drug is administered to the patient at appropriate time intervals (e.g., simultaneously with a buntanetap) and via an appropriate route of administration (e.g., oral, subcutaneous, intravenous, intramuscular). In some implementations, where possible, the antihypertensive drug (e.g., an alpha-adrenergic blocker) is administered together with a buntanetap-type drug in a single formulation.

[0239] The antihypertensive drug may be administered in therapeutic doses, as exemplified below:

[0240] In some embodiments, the antihypertensive drug is administered at a subtherapeutic dose, compared to the dose described above.

[0241] Pharmaceutical Compositions and Therapies

[0242] The administration of the compounds useful in this invention can be achieved in a variety of different ways using methods known in the art. Therefore, the methods of treatment and prevention of this invention cover the practice of the methods of this invention using pharmaceutical compositions comprising the compounds useful in this invention. The pharmaceutical compositions of this invention may comprise (i) a buntanetap or a compound similar to buntanetap (“compound (1)”) and (2) an antihypertensive drug (“compound (2)”) formulated together with one or more pharmaceutically acceptable excipients and administered in a pharmaceutical formulation.

[0243] Alternatively, the pharmaceutical composition may consist of one of compounds (1) or (2) with one or more pharmaceutically acceptable excipients. In such embodiments, compounds (1) and (2) are administered separately, but in a manner that allows them to provide overlapping therapeutic effects.

[0244] The relative amounts of the active ingredient, pharmaceutically acceptable carrier, and any additional ingredients in the pharmaceutical compositions of the present invention will vary depending on the identity, size, and condition of the subject being treated, and further on the route of administration of the composition. For example, the composition may contain 0.1% to 100% (w / w) of the active ingredient.

[0245] Although the description of the pharmaceutical compositions provided herein is primarily directed toward pharmaceutical compositions suitable for ethical administration to humans, those skilled in the art will understand that such compositions are generally suitable for administration to a wide variety of animals. Modifications to pharmaceutical compositions suitable for human administration to make said compositions suitable for administration to a wide variety of animals are well known, and pharmacologists of ordinary skill are able to design and perform such modifications with only ordinary (if any) experiments. Subjects contemplated for administration of the pharmaceutical compositions of the present invention include, but are not limited to, humans and other primates, including commercially relevant mammals such as, for example, non-human primates, cattle, pigs, horses, sheep, cats, and dogs.

[0246] Typically, the dose of buntanetap administered to animals, preferably humans, in the method of the present invention ranges from 0.5 μg to about 50 mg per kilogram of animal body weight. While the exact dose will vary depending on a number of factors, including but not limited to the type and disease state of the animal being treated, the animal's age, and the route of administration, the dose of the compound will preferably vary between about 1 μg and about 10 mg per kilogram of animal body weight. More preferably, the dose will vary between about 3 μg and about 30 mg per kilogram of animal body weight.

[0247] Pharmaceutical compositions that can be used in the methods of this invention can be prepared, packaged, or marketed in formulations suitable for oral, parenteral, topical, buccal, or other routes of administration. Other envisioned formulations include projected nanoparticles, liposome formulations, re-blocked red blood cells containing the active ingredient, and immunology-based formulations.

[0248] The pharmaceutical compositions of the present invention can be prepared, packaged, or marketed in bulk form, as a single unit dose, or as multiple single unit doses (e.g., buntanetap and antihypertensive drugs). As used herein, a “unit dose” is a discrete amount of a pharmaceutical composition containing a predetermined amount of active ingredient. The amount of active ingredient is generally equal to the dose of active ingredient to be administered to a subject or a convenient fraction of that dose, such as, for example, one-half or one-third of that dose.

[0249] The compositions of the present invention may consist of a single active ingredient in a form suitable for administration to (human) subjects or patients, or the compositions may contain at least one active ingredient and one or more pharmaceutically acceptable excipients.

[0250] In one embodiment, the compositions of the present invention are prepared using one or more pharmaceutically acceptable carriers. Useful pharmaceutically acceptable carriers include, but are not limited to, glycerol, water, saline, ethanol, and other pharmaceutically acceptable salt solutions such as phosphates and salts of organic acids. Examples of these and other pharmaceutically acceptable carriers are described in Remington's Pharmaceutical Sciences (1991, Mack Publication Co., New Jersey). The carrier may be a solvent or dispersion medium containing, for example, water, ethanol, polyols (e.g., glycerol, propylene glycol, and liquid polyethylene glycol), suitable mixtures thereof, and vegetable oils.

[0251] The formulation may be used in combination with conventional excipients, i.e., pharmaceutically acceptable organic or inorganic carrier substances suitable for oral, vaginal, parenteral, nasal, intravenous, subcutaneous, enteral, or any other suitable route of administration known in the art. The pharmaceutical formulation may be sterilized and, if desired, mixed with excipients such as lubricants, preservatives, stabilizers, wetting agents, emulsifiers, salts affecting osmotic pressure, buffers, colorants, flavoring agents, and / or aromatic substances. If desired, they may also be combined with other active agents, such as other analgesics.

[0252] As used herein, “additional ingredients” include, but are not limited to, one or more of the following: excipients; surfactants; dispersants; inert diluents; granulators and disintegrants; binders; lubricants; sweeteners; flavorings; colorants; preservatives; physiologically degradable compositions such as gelatin; aqueous media and solvents; oily media and solvents; suspending agents; dispersants or wetting agents; emulsifiers, modifiers; buffers; salts; thickeners; fillers; emulsifiers; antioxidants; antibiotics; antifungals; stabilizers; and pharmaceutically acceptable polymers or hydrophobic materials. Other “additional ingredients” that may be included in the pharmaceutical compositions of the present invention are known in the art and described, for example, in Genaro (1985, Remington's Pharmaceutical Sciences, Mack Publishing Co., Easton, PA), which are incorporated herein by reference.

[0253] The compositions of the present invention may contain from about 0.005% to 2.0% preservative by weight of the total composition. The preservative is used to prevent spoilage upon exposure to environmental contaminants. Examples of preservatives that can be used according to the invention include, but are not limited to, those selected from the group consisting of: benzyl alcohol, sorbic acid, parabens, imidazolidinyl esters, and combinations thereof. Particularly preferred preservatives are combinations of about 0.5% to 2.0% benzyl alcohol and 0.05% to 0.5% sorbic acid.

[0254] The composition may include an antioxidant and a chelating agent that inhibits the degradation of the compound. For some compounds, preferred antioxidants are BHT, BHA, α-tocopherol, and ascorbic acid, preferably ranging from about 0.01% to 0.3%, and more preferably from 0.03% to 0.1% by weight of BHT based on the total weight of the composition. Preferably, the chelating agent is present in an amount of 0.01% to 0.5% by weight of the total weight of the composition. Particularly preferred chelating agents include ethylenediaminetetraacetic acid (e.g., disodium ethylenediaminetetraacetate) and citric acid, ranging from about 0.01% to 0.20% by weight of the total weight of the composition, and more preferably from 0.02% to 0.10%. The chelating agent can be used to chelate metal ions in the composition that may be detrimental to the shelf life of the formulation. While BHT and disodium ethylenediaminetetraacetate are particularly preferred antioxidants and chelating agents, respectively, for some compounds, other suitable and equivalent antioxidants and chelating agents can therefore be substituted, as will be known to those skilled in the art.

[0255] Liquid suspensions can be prepared using conventional methods to suspend the active ingredient in an aqueous or oily medium. Aqueous media include, for example, water and isotonic saline. Oily media include, for example, almond oil, oily esters, ethanol, vegetable oils such as peanut oil, olive oil, sesame oil, or coconut oil, fractionated vegetable oils, and mineral oils such as liquid paraffin. Liquid suspensions may also contain one or more additional ingredients, including but not limited to suspending agents, dispersants or wetting agents, emulsifiers, modifiers, preservatives, buffers, salts, flavoring agents, coloring agents, and sweeteners. Oily suspensions may also contain thickeners. Known suspending agents include, but are not limited to, sorbitol syrup, hydrogenated edible fats, sodium alginate, polyvinylpyrrolidone, tragacanth gum, gum arabic, and cellulose derivatives such as sodium carboxymethyl cellulose, methylcellulose, and hydroxypropyl methylcellulose. Known dispersants or wetting agents include, but are not limited to, naturally occurring phospholipids such as lecithin, condensation products of oxidized alkenes and fatty acids, condensation products of long-chain aliphatic alcohols, condensation products of partial esters derived from fatty acids and hexitols, or condensation products of partial esters derived from fatty acids and hexitol anhydrides (e.g., polyoxyethylene stearate, heptadecanethoxylated cetyl alcohol, polyoxyethylene sorbitan monooleate, and polyoxyethylene dehydrated sorbitan monooleate, respectively). Known emulsifiers include, but are not limited to, lecithin and gum arabic. Known preservatives include, but are not limited to, methylparaben, ethylparaben, or n-propylparaben, ascorbic acid, and sorbic acid. Known sweeteners include, for example, glycerin, propylene glycol, sorbitol, sucrose, and saccharin. Known thickeners for oily suspensions include, for example, beeswax, paraffin wax, and cetyl alcohol.

[0256] Liquid solutions of the active ingredient in aqueous or oily solvents can be prepared in substantially the same manner as liquid suspensions, the main difference being that the active ingredient is dissolved rather than suspended in the solvent. As used herein, an "oily" liquid is a liquid containing carbon-containing liquid molecules and exhibiting less polarity than water. Liquid solutions of the pharmaceutical compositions of the present invention may contain each of the components described with respect to liquid suspensions, but it should be understood that suspending agents do not necessarily contribute to the dissolution of the active ingredient in the solvent. Aqueous solvents include, for example, water and isotonic saline. Oily solvents include, for example, almond oil, oily esters, ethanol, vegetable oils such as peanut oil, olive oil, sesame oil or coconut oil, fractionated vegetable oils, and mineral oils such as liquid paraffin.

[0257] The powder and granule formulations of the pharmaceutical preparations of this invention can be prepared using known methods. Such formulations can be administered directly to a subject, used for example to form tablets, fill capsules, or to prepare aqueous or oily suspensions or solutions by adding an aqueous or oily medium thereto. Each of these formulations may further comprise one or more of a dispersant or wetting agent, a suspending agent, and a preservative. Other excipients, such as fillers and sweeteners, flavoring agents, or coloring agents, may also be included in these formulations.

[0258] Except as disclosed elsewhere herein, controlled-release or sustained-release formulations of the compositions of the present invention can be prepared using conventional techniques. In some cases, the dosage form to be used may provide a slow or controlled release of one or more of the active ingredients, using, for example, hydroxypropyl methylcellulose, other polymer matrices, gels, permeable membranes, permeation systems, multilayer coatings, microparticles, liposomes or microspheres, or combinations thereof, to provide a desired release profile in varying proportions. Suitable controlled-release formulations known to those skilled in the art, including those described herein, can be readily selected for use in the compositions of the present invention.

[0259] The controlled release of an active ingredient can be stimulated by various inducers, such as pH, temperature, enzymes, water, or other physiological conditions or compounds. In the context of this invention, the term "controlled-release component" is defined herein as one or more compounds that promote the controlled release of an active ingredient, including but not limited to polymers, polymer matrices, gels, permeable membranes, liposomes, nanoparticles or microspheres, or combinations thereof.

[0260] The routes of administration for any composition of the present invention include oral, nasal, rectal, parenteral, sublingual, transdermal, transmucosal (e.g., sublingual, lingual, buccal, urethral, ​​vaginal (e.g., vaginal and perivallary), intranasal and rectal), intravesical, intrapulmonary, intraduodenal, intragastric, intrathecal, intrasheathal, subcutaneous, intramuscular, intradermal, intraarterial, intravenous, intrabronchial, inhalation and local administration.

[0261] For oral administration, tablets, sugar-coated pills, liquids, drops, capsules, pouches, and gel capsules are particularly suitable. Other formulations suitable for oral administration include, but are not limited to, powder or granule formulations, aqueous or oily suspensions, aqueous or oily solutions, pastes, gels, toothpastes, mouthwashes, coatings, oral cleansers, or emulsions. Compositions for oral administration can be prepared according to any method known in the art, and such compositions may contain one or more inert, non-toxic pharmaceutical excipients. Such excipients include, for example, inert diluents such as lactose; granulating and disintegrants such as corn starch; binders such as starch; and lubricants such as magnesium stearate. The oral compositions of the present invention are in the form of tablets or capsules prepared by conventional means with pharmaceutically acceptable excipients such as binders; fillers; lubricants; disintegrants; or wetting agents.

[0262] Tablets may be uncoated, or they may be coated using known methods to achieve delayed disintegration in the gastrointestinal tract of a subject, thereby providing sustained release and absorption of the active ingredient. For example, materials such as glyceryl monostearate or glyceryl distearate may be used to coat tablets. Further examples include tablets coated using methods described in U.S. Patent Nos. 4,256,108, 4,160,452, and 4,265,874 to form osmotic controlled-release tablets. Tablets may also contain sweeteners, flavoring agents, coloring agents, preservatives, or combinations thereof to provide a pharmaceutically elegant and palatable formulation. For oral administration, if necessary, tablets may be coated using appropriate methods and coating materials such as the OPADRY® film coating system (e.g., OPADRY® OY, OYC, organic enteric OY-P, aqueous enteric OY-A, OY-PM and OPADRY® White, 32K18400) available from Colorcon, West Point, Pa.

[0263] Hard capsules containing active ingredients can be prepared using physiologically degradable compositions such as gelatin. These hard capsules contain the active ingredient and may also contain additional ingredients, including, for example, inert solid diluents such as calcium carbonate, calcium phosphate, or kaolin. Soft gelatin capsules containing active ingredients can be prepared using physiologically degradable compositions such as gelatin. These soft capsules contain the active ingredient, which can be mixed with an aqueous or oily medium such as peanut oil, liquid paraffin, or olive oil.

[0264] Liquid formulations for oral administration may be in the form of solutions, syrups, or suspensions. These liquid formulations may be prepared using conventional methods with pharmaceutically acceptable additives such as suspending agents (e.g., sorbitol syrup, methylcellulose, or hydrogenated edible fats); emulsifiers (e.g., lecithin or gum arabic); non-aqueous media (e.g., almond oil, oily esters, or ethanol); and preservatives (e.g., methylparaben, propylparaben, or sorbic acid). Liquid formulations of the pharmaceutical compositions of the present invention suitable for oral administration may be prepared, packaged, and marketed in liquid form or as a dry product intended to be reconstituted with water or other suitable media prior to use.

[0265] Tablets containing an active ingredient can be prepared, for example, by compression or molding of the active ingredient, optionally together with one or more additional ingredients. Compressed tablets can be prepared by compressing the active ingredient in a free-flowing form, such as a powder or granules, in a suitable apparatus, optionally mixed with one or more binders, lubricants, excipients, surfactants, and dispersants. Molded tablets can be prepared by molding a mixture of the active ingredient, a pharmaceutically acceptable carrier, and a liquid sufficient to wet the mixture in a suitable apparatus. Pharmaceutically acceptable excipients for manufacturing tablets include, but are not limited to, inert diluents, granulators and disintegrants, binders, and lubricants. Known dispersants include, but are not limited to, potato starch and sodium carboxymethyl starch. Known surfactants include, but are not limited to, sodium lauryl sulfate. Known diluents include, but are not limited to, calcium carbonate, sodium carbonate, lactose, microcrystalline cellulose, calcium phosphate, dicalcium phosphate, and sodium phosphate. Known granulators and disintegrants include, but are not limited to, corn starch and alginate. Known binders include, but are not limited to, gelatin, gum arabic, pregelatinized corn starch, polyvinylpyrrolidone, and hydroxypropyl methylcellulose. Known lubricants include, but are not limited to, magnesium stearate, stearic acid, silica, and talc.

[0266] As used herein, “parenteral administration” of a pharmaceutical composition includes any route of administration characterized by physically destroying the subject’s tissue and administering the pharmaceutical composition through the site of such destruction. Therefore, parenteral administration includes, but is not limited to, administering the pharmaceutical composition by injection, application through a surgical incision, or application through a non-surgical wound that penetrates tissue. In particular, contemplated parenteral administration includes, but is not limited to, intraocular, intravitreal, subcutaneous, intraperitoneal, intramuscular, intrasternal, intratumoral, and renal dialysis infusion techniques.

[0267] Pharmaceutical compositions suitable for parenteral administration comprise an active ingredient in combination with a pharmaceutically acceptable carrier such as sterile water or sterile isotonic saline. Such formulations can be prepared, packaged, or marketed in a form suitable for bolus or continuous administration. Injectable formulations can be prepared, packaged, or marketed in unit dosage forms, such as in ampoules or in multi-dose containers containing preservatives. Formulations for parenteral administration include, but are not limited to, suspensions, solutions, emulsions, pastes, and implantable sustained-release or biodegradable formulations in oily or aqueous media. Such formulations may also contain one or more additional ingredients, including but not limited to suspending agents, stabilizers, or dispersants. In one embodiment of a formulation for parenteral administration, the active ingredient is provided in dry (i.e., powder or granules) form for reconstitution with a suitable media (e.g., sterile pyrogen-free water) prior to the reconstituted composition for parenteral administration.

[0268] The pharmaceutical compositions of the present invention can be prepared, packaged, or marketed in formulations suitable for topical administration. Delivering compounds (including drugs or other therapeutic agents) to the skin (dermal drug delivery) or through the skin into the body (transdermal drug delivery) has several advantages. Transdermal compound delivery provides an attractive alternative to injectable and oral medications.

[0269] Other dosage forms of the present invention include those described in U.S. Patent Nos. 6,340,475, 6,488,962, 6,451,808, 5,972,389, 5,582,837, and 5,007,790. Other dosage forms of the present invention also include those described in U.S. Patent Applications Nos. 20030147952, 20030104062, 20030104053, 20030044466, 20030039688, and 20020051820. Other dosage forms of the present invention include those described in PCT applications WO 03 / 35041, WO 03 / 35040, WO 03 / 35029, WO 03 / 35177, WO 03 / 35039, WO02 / 96404, WO 02 / 32416, WO 01 / 97783, WO 01 / 56544, WO 01 / 32217, WO 98 / 55107, WO 98 / 11879, WO 97 / 47285, WO 93 / 18755, and WO 90 / 11757.

[0270] It should be understood that wherever values ​​and ranges are provided herein, all values ​​and ranges covered by such values ​​and ranges are intended to be covered within the scope of this invention. Furthermore, all values ​​falling within these ranges, as well as the upper or lower limits of the value ranges, are also contemplated by this application.

[0271] Detailed description of preferred embodiments

[0272] The following embodiments further illustrate various aspects of the invention. They are provided for illustrative purposes only, and the invention is not limited to these embodiments, but covers all variations that are obvious as a result of the teachings provided herein.

[0273] Example 1

[0274] Three Phase I clinical studies have established the safety profile of buntanetap. Pharmacokinetic analyses have demonstrated that this small, lipophilic molecule readily enters the brain at concentrations approximately eight times higher than in plasma. Importantly, buntanetap at a dose of 4 x 60 mg / day normalized levels of APP, Tau, and αSYN in the cerebrospinal fluid (CSF) of MCI subjects. Buntanetap has a half-life of >12 h in the CSF of MCI subjects, and its effects in reducing these neurotoxic proteins and inflammation persist throughout the entire 12 h sampling period following the last dose (Maccecchini, et al., “Buntanetap (Posiphen) as a Candidate Drug to Lower CSF Amyloid Precursor Protein, Amyloid-β Peptide and τ Levels: Target Engagement, Tolerability and Pharmacokinetics in Humans”, J. Neurosurg. Psychiatry 2012;83:894-902). Therefore, we conclude that a much lower once-daily dose of buntanetap would be effective in the proposed study. Indeed, a much lower dose was investigated in a dual phase 2 study of Alzheimer's / Parkinson's disease conducted and completed in 2021 (effective IND #72,654). This dual phase 2 clinical trial enrolled 14 patients with AD (Alzheimer's disease) and 54 patients with PD (Parkinson's disease), treating them with once-daily buntanetap for more than 25 days. The 14 AD patients received 80 mg QD or placebo, while the 54 PD patients received 5, 10, 20, 40, or 80 mg QD or placebo. In short, the data showed that in both AD and PD patients, (a) buntanetap crossed the blood-brain barrier, (b) reduced neurotoxicity protein biomarkers, (c) reduced inflammatory markers, (d) improved axonal and synaptic function, and most importantly, improved affected function in both patient populations. In AD patients, buntanetap improved cognition as measured by ADAS-Cog11 and WAIS coding speed (achieving statistical significance at an 80 mg dose relative to baseline rather than placebo).In PD patients, it improved motor function as measured by MDS-UPDRS (parts II, III, IV, and total) at all doses, with the greatest improvements at 10 and 20 mg, and improved WAIS speed and accuracy (statistically significant relative to placebo in the 5 mg, 20 mg, and 80 mg dose groups [p<0.05] (in a broader study population [n=54]), and statistically significant improvements were also reported for the total at all doses [p<0.001]). The data demonstrate the potential benefits of reducing neurotoxic aggregate overexpression for inflammation, axonal and synaptic function, and cognitive and functional health. We anticipate that a larger sample population will allow buntanetap to fully demonstrate the statistically significant cognitive and functional improvements resulting from the normalization of neurotoxic aggregate levels in a future planned AD study, as has already been demonstrated in PD (Fang et al., Prev Alz Dis2022).

[0275] Buntanetap's effects on neurotoxic proteins. This drug reduces APP levels in neuroblastoma cells in vitro (Mikillineni et al: Parkinson's Disease; Volume 2012, Article ID142372, 13 pages. The Anticholinesterase Phenserine and Its Enantiomer Buntanetap as 5' Untranslated-Region-Directed Translation Blockers of the Parkinson's Alpha Synuclein Expression). It also reduces APP and all its fragments in APP / PS1 transgenic mice (AF Teich, et al., Alzheimer's & Dementia: Translational Research & Clinical Interventions 4 (2018) 37-45).

[0276] Buntanetap also reduced tau in vitro (Peter Davies Laboratory, Hofstra University, unpublished observations) and in vivo in human tau mice (Peter Davies Laboratory, Hofstra University, unpublished observations). Buntanetap further reduced αSYN in neuroblastoma cells in vitro and in the brain and intestine of transgenic Parkinson's animals in vivo (Kuo et al. Am J Neurodegener Dis 2019;8(1):1-15). www.AJND.us / ISSN:216 591X / AJND0086080: Translational inhibition of α-synuclein by Buntanetap (posiphen) normalizes distal colon motility in transgenic Parkinson mice).

[0277] Efficacy of Buntanetap in treating neurodegenerative diseases in animal models: restoration of memory and learning in APP / PS1 transgenic (tg) mouse models of AD; restoration of memory and learning in Ts65dn mouse models of Down syndrome (DS) [W. Mobley, UCSD, 2020 submission]; protection of the retina in acute glaucoma [J Sundstrom; Hershey Medical School]; restoration of colonic motility in human SNCAA53T tg mouse models of PD (Kuo et al., Am J Neurodegener Dis 2019;8(1):1-15 www.AJND.us / ISSN:216 591X / AJND0086080:Translational inhibition of α-synuclein by Buntanetap normalizes distal colonmotility in transgenic Parkinson mice); protection of memory and learning in rats with traumatic brain injury (M-FChesselet, 2020 submission).

[0278] Buntanetap's Reversal of the Neurotoxicity Cascade: The mechanism of action of buntanetap involves the regulation of APP, Tau, and αSYN expression by IRP1 and iron, and is associated with the way these proteins contribute to neurodegeneration by accumulating into toxic aggregates that impair axonal transport and synaptic transmission, inducing inflammation, and ultimately leading to neuronal death (as previously described). By reducing APP, Tau, and αSYN levels, buntanetap treatment halts this toxicity cascade. Supporting this hypothesis are evidence that buntanetap: normalizes anterograde and retrograde vesicle transport in fully differentiated Down syndrome neurons [Chen et al.]; normalizes impaired synaptic transmission in the striatum of rats after traumatic brain injury (TBI) [MF Chesselet; UCLA] and the hippocampus of APP / PS1 tg mice; reduces inflammation in human CSF in MCI subjects and in the brains of rats after TBI; protects neurons in the substantia nigra of rats after TBI and neurons in a rat model of acute glaucoma (J Sundstrom; Hershey Medical School); and reduces the levels of huntingtin protein through translational suppression (Chen, X.-Q.; Barrero, CA; Vasquez-Del Carpio, R.; Reddy, EP; Fecchio, C.; Merali, S.; Deglincerti, A.; Fang, C.; Rogers, J.; Maccecchini, ML. Posiphen Reduces the Levels of Huntingtin Protein Through Translation Suppression). Pharmaceutics 2021, 13, 2109. https: / / doi.org / 10.3390 / pharmaceutics13122109; and has been shown to be safe and promising in patients with Alzheimer's and Parkinson's diseases (Fang et al., Prev Alz Dis 2022).

[0279] The AD field has long been dominated by approaches that prevent APP processing or remove Aβ in one of its various forms. These are downstream targets; buntanetap prevents the translational synthesis of two major proteins involved in AD—APP and tau—and should therefore remove all downstream consequences resulting from these proteins. Similarly, the PD field has focused primarily on inhibiting the accumulation of αSYN aggregates and the role of other proteins in this pathway, including LRRK or Parkin. Again, buntanetap prevents αSYN synthesis, and therefore should stop the pathological cascade at the first step. Our data suggest that by normalizing APP / Aβ, Tau / phosphorylated-Tau, and αSYN levels, buntanetap normalizes axonal transport, reduces inflammation, and protects neurons from death. (Mobley 2020, submitted for publication; Chesselet 2020, submitted for publication).

[0280] Example 2A

[0281] Figure 1 In vitro APP, showing that buntanetap reduces APP in SH-SY-5Y human neuroblastoma cells in a dose-dependent manner. The left side is a Western blot showing the inhibition of APP by buntanetap at concentrations of 0, 0.1, 1, 5, and 10 µM relative to the actin standard, and a graph showing the same data plotted for statistical analysis purposes.

[0282] Figure 2AIn vivo APP. This study was conducted to demonstrate the role of buntanetap in inhibiting the translation of APP and its fragments in an in vivo AD model. The tables in Figure 2 show that buntanetap treatment in APP / PS1 transgenic AD mice reduced APP and its fragments in the hippocampus. GAPDH and synaptophysin served as loading controls. Figure 2 also includes a set of plots showing the relative density of APP versus control and time after buntanetap treatment; the relative density of CTFβ versus control and time after buntanetap treatment; the relative density of CTFα versus control and time after buntanetap treatment; the level of Aβ42 in brain tissue versus control and time after buntanetap treatment; and the level of Aβ40 in brain tissue versus control and time after buntanetap treatment. Finally, Figure 2 also includes a Western blot showing the levels of APP, NSB, CTFβ, and CTFα over time (minutes) after buntanetap treatment. In APP / PS1 mice expressing human mutations associated with familial AD, data showed that buntanetap treatment reduced APP and all related peptides in the hippocampus for at least 9 hours after the last dose.

[0283] Example 2B

[0284] A randomized, double-blind, placebo-controlled phase II / III trial was conducted to investigate the efficacy, safety, and tolerability of buntanetap in patients with mild to moderate Alzheimer's disease (AD). This was a dose-range study in which patients received one of three doses of buntanetap (7.5 mg, 15 mg, or 30 mg) or placebo in addition to standard of care for 12 weeks. More than 700 patients were screened for this study, with 353 patients enrolled and 325 patients completing the study at 54 centers across the United States. The study included patients with mild to moderate AD who had a baseline Mini-Mental State Examination (MMSE) score of 14 to 24. (www.clinicaltrials.gov (NCT05686044)).

[0285] In addition to safety, the trial assessed changes in two co-primary endpoints: the Alzheimer's Disease Assessment Scale-Cognitive Subscale 11 (ADAS-Cog 11) and the Alzheimer's Disease Collaborative Study Clinician Global Impression Change (ADCS-CGIC), which assesses cognitive and daily living activities. The study monitored safety and collected plasma to measure several biomarkers to assess disease status, potential disease progression, and treatment efficacy.

[0286] In patients with mild Alzheimer's disease (AD), significantly greater improvements in ADAS-Cog 11 scores were observed at all treatment doses compared to placebo. Analysis focusing on early-stage AD patients with positive biomarkers (MMSE 21-24, pTau217 / tTau ≥ 4.2%) revealed highly statistically significant differences between ADAS-Cog 11 and placebo, as well as between ADAS-Cog 11 and baseline, at all three dose levels and at the combined dose level. Figure 2B Treatment response in this study was not related to patient age or sex.

[0287] At the end of 3 months of treatment, the placebo group showed a slight improvement (LSM(SE), 0.26 (0.91)), but no significant difference from baseline. However, all three buntanetap treatment groups showed statistically significant improvements relative to their respective baselines (7.5 mg: 2.19 (0.87), p = 0.013; 15 mg: 2.79 (0.81), p = 0.001; 30 mg: 3.32 (0.82), p < 0.001). The 15 mg and 30 mg treatment groups also showed statistically significant improvements relative to the placebo group (p = 0.042 and 0.015, respectively). EOT - End of Treatment* P < 0.05; ** P < 0.01; *** P < 0.001.

[0288] When baseline MMSE scores in AD-positive patients were subdivided according to the pTau217 / tTau > 4.2%, a dose-dependent relationship with baseline MMSE was observed. The conclusion is that patients with mild AD responded more significantly to buntanetap treatment compared to patients with more advanced AD. The response in the 30 mg dose group was R² = 0.17 (R² or coefficient of determination), p < 0.001, indicating statistical significance of the MMSE score, which was not evident in the placebo group. Figure 2C This confirms the previous statement. Figure 2B The effects of buntanetap are shown.

[0289] The conclusion was that the proportion of participants who experienced improvement was three times greater in the 30mg group compared to the placebo group (Table 1A).

[0290] Table 1A

[0291] The conclusion is that Figure 2B and Figure 2C The data presented demonstrates the efficacy of buntanetap in early-stage AD patients.

[0292] Example 3

[0293] Figure 3This was an early mechanism validation (POM) study using well-tolerated doses of buntanetap in subjects with mild cognitive impairment (MCI). Plasma and cerebrospinal fluid (CSF) samples were obtained before and 10 days after administration of buntanetap to MCI subjects to analyze the levels of secretory(s)APPα and APPβ, as well as Aβ42, Tau (total Tau and phosphorylated Tau), and inflammatory markers. Figure 3 This study showed decreased levels of APP / Aβ, tau / phosphate-tau, and α-synuclein in the cerebrospinal fluid of patients with mild cognitive impairment. In this study, buntanetap normalized these aggregated proteins in the CSF of MCI subjects, consistent with data observed in animals.

[0294] Example 4

[0295] A study has established an association between terazosin, doxazosin, or alfuzosin and a reduced risk of Lewy body dementia (“DLB”). Hart et al., Association of Terazosin, Doxazosin, or Alfuzosin Use and Risk of Dementia With Lewy Bodies in Men, Neurology, July 23, 2024 issue. The study analyzed data from over 600,000 men.

[0296] The study reported that men who recently started using terazosin, doxazosin, or alfuzosin had a lower risk of developing DLB than matched men using tamsulosin (n = 242,716,728,256 person-years, hazard ratio [HR] 0.60, 95% CI 0.50–0.71) or 5ARI (n = 130,872,399,316 person-years, HR 0.73, 95% CI 0.57–0.93), while the risk for men using tamsulosin was similar to that for men using 5ARI (n = 159,596,482,280 person-years, HR 1.17, 95% CI 0.96–1.42). "Specifically, it has a 40% lower risk compared to tamsulosin and a 37% lower risk compared to 5ARI." Tsai, ProstateMeds Slash Dementia Risk by up to 40 Percent: Study, Epoch Health, June 26, 2024.

[0297] This study provides Class III evidence that the use of terazosin, doxazosin, or alfuzosin reduces the rate of DLB ​​development in adult men.

[0298] Although the present invention has been disclosed with reference to specific embodiments, it will be apparent to those skilled in the art that other embodiments and variations of the invention can be devised without departing from the true spirit and scope of the invention. All patents and publications cited herein are incorporated herein by reference in their entirety. The appended claims are intended to be construed as encompassing all such embodiments and equivalent variations.

Claims

1. A method of treating a neurodegenerative disease, comprising administering to a person in need a formulation containing buntanetap or a pharmaceutically acceptable salt thereof and an alpha-adrenergic blocker.

2. The method according to claim 1, wherein the α-adrenergic blocker is selected from the group consisting of terazosin, doxazosin, alfuzosin, and pharmaceutically acceptable salts thereof.

3. The method according to claim 1 or 2, wherein the neurodegenerative disease is selected from the group consisting of Alzheimer's disease, chronic traumatic encephalopathy, frontotemporal dementia, Parkinson's disease, alpha-synucleinosis, prion disease, Down syndrome, Huntington's disease, amyotrophic lateral sclerosis, and multiple sclerosis.

4. The method according to claim 3, wherein the neurodegenerative disease is Alzheimer's disease.

5. The method according to claim 3, wherein the formulation is administered orally, parenterally, intravenously, subcutaneously, sublingually, via suppository, intranasally, topically, transdermally, or via a subcutaneous implant.

6. The method of claim 3, wherein the formulation comprises about 0.1 mg to about 0.9 mg of buntanetap or a pharmaceutically acceptable salt thereof, and is administered orally once daily.

7. A method of treating a neurodegenerative disease, comprising administering a combination of medications to a person in need: (1) A certain amount of buntanetap or a pharmaceutically acceptable salt thereof, and (2) A certain amount of α-adrenergic blocker.

8. The method of claim 7, wherein the α-adrenergic blocker is selected from the group consisting of terazosin, doxazosin, alfuzosin, and pharmaceutically acceptable salts thereof.

9. The method of claim 7, wherein compounds (1) and (2) are administered separately, but such that they provide overlapping therapeutic effects.

10. The method of claim 7, wherein the amount of buntanetap or a pharmaceutically acceptable salt thereof is from about 0.1 mg to about 0.9 mg, and the buntanetap or a pharmaceutically acceptable salt thereof is administered orally once daily.

11. A pharmaceutical composition comprising (i) buntanetap or a pharmaceutically acceptable salt thereof, (ii) α-adrenergic blockers; and (iii) At least one pharmaceutically acceptable excipient.

12. The pharmaceutical composition of claim 11, wherein the α-adrenergic blocker is selected from the group consisting of terazosin, doxazosin, alfuzosin, and pharmaceutically acceptable salts thereof.

13. The pharmaceutical composition according to claim 15, wherein it is a tablet.

14. The pharmaceutical composition of claim 13, wherein the tablet comprises about 0.1 mg to about 0.9 mg of buntanetap or a pharmaceutically acceptable salt thereof.

15. The method of claim 14, wherein the α-adrenergic blocker is terazosin or a pharmaceutically acceptable salt thereof.

Citation Information

Patent Citations

  • (3aR)-1,3a,8-Trimethyl-1 ,2,3,3a,8,8a-hexahydropyrrolo[2,3-b]indol-5-yl phenylcarbamate and methods of treating or preventing neurodegeneration

    US10383851B2

  • Extending the duration of drug release within the stomach during the fed mode

    US20020051820A1

  • Extending the duration of drug release within the stomach during the fed mode

    US20030039688A1

  • Pharmacological inducement of the fed mode for enhanced drug administration to the stomach

    US20030044466A1

  • Optimal polymer mixtures for gastric retentive tablets

    US20030104053A1